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Zusammenfassung 
Das WHO/UNAIDS „Global summary of the AIDS epidemic“, erschienen im Dezember 
2006, schätzt, dass 39,5 Millionen Menschen mit HIV leben, 4,3 Millionen in 2006 infiziert 
wurden und 2,9 Millionen Menschen im gleichen Jahr an AIDS gestorben sind. In den 
Industrieländern werden HIV-1 infizierte Personen mit einer Kombination von 
antiretroviralen Medikamenten behandelt (hochaktive antiretrovirale Therapie, HAART). Die 
Therapie verringert die Virenlast auf ein nicht nachweisbares Niveau, ist aber nicht in der 
Lage das Virus zu eliminieren. Folglich ist eine lebenslange HAART Therapie erforderlich. 
Einige Probleme sind mit HAART in den Industrieländern, in denen die meisten HIV-1 
infizierten Menschen leben verbunden: Nebenwirkungen, vorschriftsmäßige Einnahme, 
Virusmutationen und hohe Kosten. Diese Beobachtungen heben die Notwendigkeit für die 
Entwicklung eines therapeutischen Impfstoffs gegen HIV-1 hervor. 
Wir führten eine Sicherheits- und Immunogenitäts-Phase I Studie durch, in der wir einen 
Impfstoff, basierend auf einem modifizierten Vaccinia Virus Ankara (MVA) Vektor, der das 
HIV-1 regulierende Protein Nef  exprimiert in zehn chronisch HIV-1 infizierten Patienten 
unter HAART verwendet haben. Die Studienteilnehmer wurden dreimal, in Woche 0, 2 und 
16 subkutan geimpft. Danach wurden alle für mindestens ein Jahr beobachtet. 
Der Impfstoff erwies sich als sicher und immunogen. Eine Zunahme der Nef-spezifischen 
CD4 T-Zell-Antworten, die zeitlich mit der Impfung in Zusammenhang steht, wurde in der 
Mehrheit der Patienten festgestellt und die beobachtete Immunantwort war der ähnlich der, 
die in einer Kohorte von Langzeit Nicht-Progressoren (LTNP) festgestellt wurde. 
Entsprechend dieser Daten verbessert sich der immunologische Status der Patienten und es 
erhöht sich die Wahrscheinlichkeit, dass geimpfte Personen die Virusproduktion kontrollieren, 
ähnlich wie es bei den LTNP der Fall ist. Interessanterweise waren die Nef-spezifischen CD4 
T-Zellen ein Jahr nach der Impfung noch nachweisbar und demonstrierten die Eigenschaft des 
Impfstoffs, eine langfristige Gedächtnisantwort auszulösen. 
MVA gehört zu dem vielversprechendsten attenuierten viralen Vektorsystem für die 
Präsentation von Antigenen und es ist einer der vielversprechendsten Impfstoffe gegen 
Pocken. HIV-1 infizierte Personen sind möglicherweise immunsupprimiert und werden als 
gefährdet für die Nebenwirkungen der klassischen Pockenschutzimpfung betrachtet. Die 
MVA-nef Impfstudie lieferte eine wertvolle Möglichkeit zur Analyse der Eigenschaften von 
MVA, Vaccinia-spezifische Immunantworten in chronisch HIV-1 infizierten Personen unter 
HAART zu induzieren. Nach der Impfung mit MVA-nef beobachteten wir eine starke 
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spezifische humorale und zelluläre Immunantwort gegen den viralen Vektor. Von Interesse ist 
hier, dass Vaccinia-spezifische Antikörper in der Lage waren, das Virus zu neutralisieren. Die 
Antikörper waren hauptsächlisch von der IgG Klasse. Die Analyse der MVA-spezifischen 
und der Nef-spezifischen Immunantworten ergab eine mögliche Interferenz zwischen den 
CD4 T-Zellen, die den viralen Vektor erkennen und den CD4 T-Zellen, die spezifisch für Nef 
sind. Tatsächlich hatten die Patienten mit den niedrigsten Nef-spezifischen CD4 T-
Zellantworten die höchsten CD4 T-Zellantworten gegen MVA und umgekehrt. Zusätzlich 
zeigte der Vaccinia naive Patient Nr. 10 die stärkste CD4 Antwort gegen Nef und eine 
niedrige CD4 Antwort gegen MVA. Diese Beobachtungen weisen auf einen möglichen 
negativen Effekt der vorhandenen Immunität gegen Vaccinia Virus hin, eine starke 
Immunantwort gegen das heterologe Antigen auszulösen. 
Die Charakterisierung der gegen MVA gerichteten Immunantwort weist auf die mögliche 
Verwendung von MVA als alternativen Impfstoff gegen Pocken und die Eigenschaft des 
MVA-nef Vektors hin, eine doppelte Impfung zu ermöglichen. Diese Daten stellen das 
Grundprinzip für die weitere Entwicklung und Prüfung des MVA-nef Impfstoffs zur 
Verfügung. 
 7
Summary 
The WHO/UNAIDS “Global summary of the AIDS epidemic” released in December 2006, 
estimates that 39.5 million of people are living with HIV, 4.3 million were newly infected in 
2006 and 2.9 million of people died of AIDS in the same year. In developed countries, HIV-1 
infected individuals are treated with a combination of antiretroviral drugs (Highly Active 
Antiretroviral Treatment, HAART). This treatment normally reduces the viral load to 
undetectable levels but is not able to eradicate the virus. Therefore, life-long administration of 
HAART is required. Several problems are associated with HAART: side effects, compliance, 
virus escape and high cost for developing countries where most HIV-1 infected individuals 
reside. These considerations highlight the need for a therapeutic vaccine against HIV-1. 
We performed a safety and immunogenicity phase I pilot study using a vaccine based on a 
modified vaccinia virus Ankara (MVA) vector expressing the HIV-1 regulatory protein Nef in 
ten chronically HIV-1 infected individuals undergoing HAART. Study subjects were 
vaccinated subcutaneously three times at week 0, 2 and 16. Afterwards, all the subjects were 
monitored for at least one year. 
The vaccine resulted to be safe and immunogenic. An increase of the Nef-specific CD4 T-cell 
responses temporally associated with the administration of the vaccine was observed in the 
majority of the individuals and the observed magnitude was similar to that observed in a 
cohort of long-term non-progressors (LTNP). These data suggest an improvement of the 
immunological status and an increased chance of the vaccinated subject to control viral 
replication as it is the case for the LTNP. Interestingly, one year after the administration of the 
vaccine CD4 T-cells specific to Nef were still detectable demonstrating the capacity of the 
vaccine to elicit a long term memory response. 
MVA is among the most promising live viral vector system for the delivery of pathogen-
derived antigens and is one of the most promising safe vaccines against smallpox. HIV-1 
infected subjects are potentially immunocompromised and are considered at risk for the side 
effects of the classical smallpox vaccination. The MVA-nef vaccination study provided a 
valuable chance to analyze the capacity of MVA to elicit vaccinia specific immune responses 
in chronically HIV-1 infected individuals under HAART. Following vaccination with MVA-
nef, we observed a strong humoral and cellular immune response specific to the viral vector. 
Of note, vaccinia specific antibodies were able to neutralize the virus and were mainly of the 
IgG class, suggesting an effective immune response.  The analysis of the MVA-specific and 
the Nef-specific immune responses highlighted a possible interference between CD4 T-cells 
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recognizing the viral vector and CD4 T-cells specific to Nef. In fact, subjects with the lowest 
Nef-specific CD4 T cell responses had the highest CD4 T cell responses to MVA and vice 
versa. In addition, the vaccinia naïve study subject number 10 was able to mount the strongest 
CD4 response to Nef and showed a low CD4 response to MVA. These important observations 
highlighted a possible negative effect of the pre-existing immunity to vaccinia virus on the 
capacity of the MVA vector to elicit a strong immune response to the genetic insert. 
The characterization of the immune response directed to MVA, highlighted the potential use 
of MVA as alternative vaccine against smallpox and the capacity of the MVA-nef vector to 
provide a double vaccination. This data provide the rationale for further development and 
testing of the MVA-nef vaccine.  
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Background 
AIDS and HIV an historical overview 
The first cases of Acquired Immunodeficiency Syndrome (AIDS) were described in 1981 in 
San Francisco and New York. Physicians noted that a group of young homosexual men was 
dying from infections and tumors that a fully competent immune system is able to control 
without problems. The first report (Gottlieb et al., 1981) described four homosexual men that 
contracted Pneumocystis carinii pneumonia, extensive mucosal candidasis and multiple viral 
infections. All the patients were lymphopenic, they had no lymphocyte proliferative response 
to soluble antigens and their responses to phytohemagglutinin were reduced. Moreover, CD4+ 
T-helper cells were almost absent. Patients were clearly in an immunodeficient status. 
In the same year, Pneumocystis carinii pneumonia associated with an immunodeficient status 
was observed in a group of injecting drug users (Masur et al., 1981), suggesting that the 
pathology was not restricted to the homosexual community. This observation was extended 
the next year when the pathology was observed in haemophiliacs (MMWR, 1982a) and in a 
20-month old child that received multiple transfusion of blood (MMWR, 1982b). It was then 
clear that the disease was transmitted via the sexual route or via the blood. 
In August 1982, the disease was being referred to as “Acquired Immune Deficiency 
Syndrome” (AIDS). This name was a summary of all the knowledge about this disease at that 
time. In fact, “Acquired” indicated that people acquired the condition rather than inherited it, 
the condition was the result of a deficiency within the immune system and it was a syndrome, 
with several manifestations, rather than a single disease. 
In 1983, Montagnier and his colleagues at the Pasteur Institute in Paris reported the discovery 
of a T-lymphotropic retrovirus in a patient at risk of AIDS, this was the virus that we now call 
human immunodeficiency virus (HIV) (Barre-Sinoussi et al., 1983). Afterwards, Gallo and 
his collegues showed that the virus discovered in Paris was the etiologic agent of AIDS (Gallo 
et al., 1984; Popovic et al., 1984; Sarngadharan et al., 1984; Schupbach et al., 1984) and 
succeeded to grow it in continuous T-cell cultures enabling the development of a blood test 
for detecting HIV. These two works opened the way to a period of intense discovery. The 
HIV genome was sequenced (Wain-Hobson et al., 1985), the HIV antigenic variation was 
discovered, the virus was found in the brain of AIDS patients (Gabuzda et al., 1986; Gartner 
et al., 1986; Stoler et al., 1986), genomic sequence variation was found in viral population 
from the same patient (von Briesen et al., 1987), macrophages were found to be target of HIV 
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(Wiley et al., 1986), various mode of transmission were elucidated, all HIV’s genes and 
proteins were defined and the HIV receptor CD4 was identified (Dalgleish et al., 1984; 
Klatzmann et al., 1984). 
In 1987, the first anti-HIV drug entered in clinical use. One year before, a study published in 
the New England Journal of Medicine demonstrated that a drug called azidothymidine (AZT) 
decreased mortality and the frequency of opportunistic infections in subjects with AIDS 
(Fischl et al., 1987). However, the same study showed severe adverse reaction including 
hematologic toxic effects, nausea, myalgia, insomnia, and severe headaches (Richman et al., 
1987). 
In 1989, a second drug, dideoxyinosine (ddI), was made available. Both AZT and ddI targeted 
the viral enzyme reverse transcriptase (RT), a key enzyme responsible for the 
retrotranscription of the viral RNA to DNA, a process that precedes the integration of the 
proviral DNA in the host cell genome. AZT and ddI are nucleoside analogues and they act as 
chain terminators in the RT reaction, blocking the virus immediately after its entry into the 
cell. The use of several nucleosides analogues was approved in the following years. However, 
the toxicity, the lack of activity in some cell types and the susceptibility to viral resistance 
were already important issues that limited the use of these drugs. 
In 1995, two trials (ACT175 trial and Delta trial) demonstrated for the first time that a 
combination of two different nucleosides analogues was more effective than an AZT 
monotherapy in delaying disease progression. 
Also in 1995, the FDA approved the drug saquinavir, the first member of a new class of anti-
HIV drugs. Saquinavir is a HIV-specific protease inhibitor. This new class of antiretroviral 
drugs inhibits the viral protease that cleaves the viral precursor proteins needed for the 
construction of a mature virion. As consequence, infected cells release immature and non-
infectious particles. 
The next obvious step was the use of a combination of reverse transcriptase inhibitors 
together with protease inhibitors. The rationale behind this strategy was that the use of several 
antiviral drugs should suppress viral replication to such low level to avoid viral escape.  This 
new strategy named highly active antiretroviral therapy (HAART) gave impressive results and 
in the 11th International Conference on AIDS in Vancouver (1996) numerous reports from 
clinical trials using HAART were presented. In 1997, the widespread use of HAART in 
developed countries drastically reduced AIDS related morbidity and mortality. However, in 
the following years it became also evident that the adverse events associated with the 
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administration of HAART and the capacity of the virus to escape would have been major 
obstacles to the complete eradication of HIV. 
Between 1995 and 1996, the main HIV-1 co-receptors were identified. The discovery that the 
CC-chemokines RANTES, MIP-1 alpha and MIP-1 beta produced by CD8 T-cells are able to 
suppress HIV-1 (Cocchi et al., 1995), opened the way to the discovery of the main HIV-1 co-
receptors CXCR4 and CCR5 (Lusso, 2006) and to the dissection of the entry mechanism of 
HIV-1. Virus entry in CD4 expressing cells is mediated by the envelope glycoprotein 
expressed on the surface of the virion (Berzofsky et al., 2004). The envelope protein is 
composed by an external subunit, the gp120, and a transmembrane subunit, the gp41 (Figure 
IA). These two subunits are arranged in trimers on the surface of the virus, with the three 
gp120 subunits forming a sort of shield protecting the three gp41 subunits. The gp120 binds 
first the main receptor CD4 (Figure IB) triggering a conformational change that exposes the 
coreceptor binding site (Figure IC). After engagement with the coreceptor (CCR5 or CXCR4), 
the fusion domain of the gp41 is exposed and can interact with the membrane of the target cell 
(Figure ID). Then, fusion between the viral and cellular membrane occurs (Figure IE). 
 
Figure I: Mechanism of HIV-1 entry in a target CD4 expressing cell. From Berzofsky et al., J. Clin. Invest. 
2004. 
The distinctive use of CCR5 or CXCR4 coreceptors for entry into target cells, identify two 
phenotypic variant of HIV-1, R5 and X4 viruses, respectively. Usually, recently infected 
individuals harbor a R5 virus while X4 viruses predominate in the late stages of the disease. 
 
 12
The advent of HAART changed the public perception of HIV and AIDS. The public began to 
perceive HIV infection as a treatable chronic disease, and the attention dedicated to HIV and 
AIDS started to decrease drastically over the time. This change of perception lead also to a 
change of the affected population. In fact, in the United Kingdom in 1999, for the first time 
the number of newly diagnosed heterosexual infected with HIV was higher than the number 
of newly diagnosed homosexual. 
In 1999, T20 an antiretroviral drug that targets the fusion process between the virus and the 
cell went into clinical trials and in 2002 at the Barcelona International Conference on AIDS, 
several groups reported on the efficacy of the new drug. 
An important milestone in the fight against HIV was the conclusion of the first phase III 
efficacy trial of the VaxGen vaccine (McCarthy, 2003a; McCarthy, 2003b). The vaccine 
contained two recombinant form of the HIV-1 Envelope protein gp120 in a monomeric form. 
Two different trials were conducted in North America (AIDSVAX B/B) and in Thailand 
(AIDSVAX B/E), and in both the reduction of the HIV infection rate and progression to 
disease between vaccinated and placebo groups resulted to be not significant. Despite the 
disappointing result, this first trial finally demonstrates what had been already shown in vitro 
in several settings; gp120 specific antibodies plays a minor role in controlling HIV replication. 
However, Env variants that permit the exposure of conserved epitopes and oligomeric forms 
of the envelope protein that include the transmembrane protein gp41 are currently available 
and under study and may represent good candidate vaccine for future clinical trials 
(Pantophlet and Burton, 2006). 
In 2006, the first “one a day” pill (Atripla) was approved for sale in the USA. It is aspected 
that this new pill will increase the compliance to HIV treatment and as direct consequence 
will decrease the emergence of escape mutants. 
In the same year, a new threat emerged; several cases of extreme drug-resistant tuberculosis 
(XDR-TB) were recorded in South Africa. HIV infected people are more susceptible to 
Mycobacterium tuberculosis infection and to progression to active TB. As a consequence, 
HIV infected people with their compromised immune system represent a favourable host for 
the emergence of XDR-TB. High prevalence of HIV infection as been found also in 
individuals seeking treatment for malaria in Uganda (Kamya et al., 2006), underscoring the 
deadly interaction between HIV and other disease that commonly affect developing countries. 
On December 2006, two randomized controlled trial of male circumcision performed in 
Kenya and Uganda (Bailey et al., 2007; Gray et al., 2007) provided evidence of a strong 
association between circumcision intervention and a reduced risk of contracting HIV. In 
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regions with high HIV incidence and prevalence, circumcision may have a profound impact in 
saving life. However, large-scale implementation of circumcision will require improvement of 
the health care system and improvement of the communication with local authorities and 
community member. 
Natural history of HIV infection 
The detailed definition of the different stages of HIV infection in humans is an important field 
of research to highlight potential vulnerabilities of the virus. For obvious reasons the majority 
of the direct information regarding the different stages of the infection has been generated on 
the SIV model while a series of indirect observations in humans confirm the model of 
infection designed in non-human primates. 
The dominant mode of transmission of HIV and SIV is through heterosexual intercourse and 
the first contact between the virus and the host occurs at the mucosal barrier (Haase, 2005). 
After crossing the mucosal barrier, the virus infects the resting memory CCR5+ CD4+ T-cells 
in the lamina propria. These are the first cells to be infected by HIV, probably because they 
are the more abundant cells that reside in the lamina propria. Although the memory CCR5+ 
CD4+ cells infected by HIV in the lamina propria have a typical resting phenotype, they are 
able to support viral replication and the virus is then able to infect activated CD4+ T-cell, 
macrophages and dendritic cells that reside as well in the lamina propria, but are less 
numerous than resting CD4+ T-cells. The observation of resting CD4+ T-cell in the lamina 
propria supporting SIV and HIV replication in vivo (Zhang et al., 1999; Zhang et al., 2004) 
contrasts with the data obtained in vitro, where lentiviral replication and T-cell activation are 
strictly connected. This contradiction might be related to the methods used to define the 
phenotype of the resting CD4 T-cells. That is probably these cells are not really resting.  
After 4 to 6 days, virions disseminate from the small founding area in the lamina propria to 
the draining lymph node and afterwards establish infection in the peripheral lymph node, the 
spleen and the gut associated lymphoid tissue (GALT). All these organs contain highly 
packed target cells, a condition that favors viral replication, and between day 10 and 14 after 
exposure virus production reaches the highest level of any stage of the infection. Virus 
replication in the GALT plays a central role in HIV-1 and SIV pathogenesis. GALT contains 
nearly half the human body’s total T-cells and the majority of the GALT CD4 T-cell 
expresses the CCR5 co-receptor. This distribution may account for the selection of CCR5 
using viruses (R5 viruses) early in the course of infection. In the GALT, large numbers of 
memory CCR5+ CD4+ T-cells are killed by direct virus infection in few days after infection 
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(Li et al., 2005; Mattapallil et al., 2005). The degree of destruction of the CD4 memory 
compartment during acute infection predicts survival in monkey infected with SIV 
(Mattapallil et al., 2006). CCR5 using viruses are then maintained during all the chronic phase 
of infection and a shift towards CXCR4 using viruses is seen only during the progression to 
AIDS. 
By two to four weeks after infection, the amount of virus in the host starts to drop down. Two 
contemporary acting mechanisms can explain the decline that follows the peak of viral load 
during the acute infection. First, the exhaustion of the resting CD4 T-cell killed by direct virus 
cytopathic effect and by virus induced apoptosis decreases the availability of target cells. 
Second, the immune system develops a strong HIV / SIV specific immune response able to 
counteract the viral production of the activated CD4 T-cells. Depletion studies performed in 
monkeys have nicely demonstrated that CD8 T-cells play a crucial role in controlling SHIV 
replication in primary infection (Matano et al., 1998). 
After the acute phase of the infection, the viral load decreases to a lower level that is 
characteristic for each individual and is called “viral set point”.  This is the typical chronic 
phase of the disease, characterized by the absence of symptom, detectable viral load (>50 
copies RNA/ml) and a slow decline in the total CD4 counts. CD8 T-cells play an important 
role also in controlling the chronic phase of the infection as demonstrated by depletion studies 
in the SIV / Macaca mulatta model (Jin et al., 1999) and contribute to stabilize the viral load 
at the viral set point in the absence of antiretroviral therapy. During the acute infection and the 
chronic phase of the disease, we assist to the formation of the viral reservoirs that will be 
maintained throughout the life of the host. HIV and SIV reservoir include the follicular 
dendritic cell network, macrophages and resting memory CD4 T-cells (Noe et al., 2005). 
In the final stage of the disease, we assist to a rapid decline of the total CD4 T-cells and to the 
rise of the viral load. At this time, patients are in a clear immunodeficient status and 
opportunistic infections begin to occur when the CD4 count falls below 200 cells/μl. From a 
virologic point of view, the terminal phase of the HIV infection is characterized by a 
phenotypic shift from the R5 to the more pathogenic X4 virus. X4 viruses dominate the late 
stages of the HIV-1 disease and are responsible of dramatic damages to the immune system 
via their capacity to infect and destroy naïve CD4 T-cells (Moore et al., 2004). 
In this scenario, the administration of antiretroviral drugs changes the natural course of HIV-1 
infection and prolongs the chronic asymptomatic phase of the disease. After administration of 
HAART, the viral load falls below 50 RNA copies/ml, CD4 count remain stable and the 
probability to develop AIDS is strongly reduced. Despite the strong reduction in plasma viral 
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load, several studies theoretically demonstrated that eradication of HIV-1 might be achieved 
only after more than 60 years of continuous antiretroviral treatment (Pierson et al., 2000). The 
main obstacle to achieve eradication in a realistic time frame is the presence of viral reservoirs 
that form a sort of protected archive for the proviral DNA (Noe et al., 2005). Since proviral 
DNA may persist inside the cell without expression of viral protein, this reservoir cannot be 
targeted with the actual technology. Therefore, eradication of HIV remains an unrealistic 
scenario.  
Vaccination 
The WHO/UNAIDS “Global summary of the AIDS epidemic” released in December 2006, 
estimates that 39.5 million of people are living with HIV, 4.3 million were newly infected in 
2006 and 2.9 million of people died of AIDS in the same year. Twenty-five million HIV 
infected people live in Sub-Saharan Africa (Figure II) where only 1 million of people were 
receiving antiretroviral treatment by June 2006.  
Sub-Saharan Africa
South/South-East Asia
 Western/Central
Europe
 North
America/Caribbean
 Eastern Europe/Central
Asia
Latin America
East Asia/Oceania
 Middle East/North
Africa
 
Figure II: Global prevalence of people living with HIV in 2006. 
Despite the efforts made to increase the access to an effective treatment and to develop 
prevention programmes the number of people infected by HIV continues to grow. In many 
countries, HIV incidence increased in young adult between 15 and 24 year of age. In Sub-
Saharan Africa, HIV epidemic affect more women than men. In South Africa 17% of young 
women (15-24 years) are infected by HIV, while only 4.4% of young men are infected (data 
from the year 2005). 
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These data highlights how important will be a vaccine against HIV, mainly in Sub-Saharan 
Africa. A prophylactic vaccine will certainly help in preventing the spread of the virus. On the 
other hand, a therapeutic vaccine is also urgently needed for the 40 million of people already 
infected by HIV. The aim of a therapeutic vaccine is to enhance pre-existing immune 
responses to such extent that a chronic pathogen can be kept under control or in the best 
scenario completely cleared (Autran et al., 2004). The main difference between a prophylactic 
and a therapeutic vaccine rely in the fact that a prophylactic vaccine has to face to a low 
amount of pathogen confined to a small area while a therapeutic vaccine has to face with large 
amount of pathogen and a generalized infection. 
The final aim of the HIV vaccine research is to obtain a prophylactic vaccine able to prevent 
infection and a therapeutic vaccine able to eliminate the virus already present in the host. 
However, several line of evidence indicates that such vaccines will not be available in a short 
time frame and a more realistic goal will be to set up partially effective vaccines. 
The aim of a partially effective prophylactic vaccine will be to limit the damage of the acute 
infection and delay the use of antiretroviral treatments. A partially effective prophylactic 
vaccine should reduce the amount of virus produced during the first weeks of infection; 
limiting the destruction of the memory CD4 T-cells in the gut associated lymphoid tissue. 
During the chronic phase of infection, the new vaccine should be able to lower the viral set 
point and delay the use of antiretroviral treatment. 
The aim of a partially effective therapeutic vaccine will be to maximize the time without 
antiretroviral treatment and provide a valuable alternative for all the people that do not have 
access to antiretroviral treatments. Actually, a therapeutic vaccine has to face to two different 
scenarios: 
• in a typical developed country where there is access to antiretroviral treatment for all 
the person that are in need and where there is the tendency to treat infected people as 
soon as possible, the vaccine will be administrated during treatment. Patients will have 
low or undetectable viral load and after vaccination they will have the option to 
interrupt treatment. 
• in developing countries, as South Africa, the vaccine will be administrated mainly to 
untreated persons and probably the viral load and CD4 count of this people will be 
unknown. The vaccine will have to face a scenario of active viral replication. 
For this reasons it will be necessary to develop two different therapeutic vaccines each one 
adapted to the situation in the field. 
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Several strategies of prophylactic and therapeutic vaccination that include the use of 
recombinant envelope proteins, synthetic peptides, virus like particles, whole inactivated 
viruses, plasmid DNA, recombinant orthopoxviruses and antigen pulsed dendritic cells have 
been already tested in humans (Egan, 2004; McMichael, 2006).  
Recombinant envelope proteins 
Since, antibodies able to neutralize HIV-1 in vitro were exclusively directed against the viral 
Envelope, initial efforts to identify a vaccine were directed toward the development of a 
vaccine based on recombinant Envelope proteins. Successive findings that antibodies elicited 
by recombinant Envelope were able to neutralize laboratory strain of HIV but not primary 
isolates grown on PBMC, tempered the initial optimism. Nevertheless, studies on 
recombinant Envelope proteins underwent phase I, II, and III trials. The VaxGen vaccines 
AIDSVAX B/B and AIDSVAX B/E were the first vaccines against HIV-1 to be tested in two 
large phase III trials in USA and Thailand, respectively (McCarthy, 2003a; McCarthy, 2003b) 
(see also “AIDS and HIV an historical overview”). In the trial performed in North America, 
5009 individuals were enrolled and in the three years study 5.8% of the placebo-receiving 
group and 5.7% of the vaccinated people became HIV-1 infected. The difference was not 
significant. The trial in Thailand confirmed the results obtained in North America. The results 
of these phase III trials were not unexpected and reflected the inability of the recombinant 
Envelope to elicit antibodies able to neutralize primary isolates in vitro. 
Despite this debacle, several efforts to improve the formulation of Envelope based vaccines 
are under way. These include, trimeric forms, Envelopes with deletions in the variable regions 
(Erfle et al., 2005), and complexes between the Envelope protein and CD4, CCR5, and 
antibody. All this variants may express hidden determinants with a key role in virus 
neutralization. Hidden determinants may be expressed also in the context of the virion that 
carries several cell derived membrane proteins. This issue will be discussed later (see 
“Vaccines to cellular proteins”) 
DNA vaccines 
DNA vaccines appeared ten years ago showing major advantages when compared to 
attenuated pathogens and live viral vectors. Attenuated pathogens induced primarily humoral 
immune responses and live viral vectors despite being able to induce a strong cytotoxic 
immune response, raised concerns about their safety in humans. In murine models, DNA 
vaccination was originally shown to induce strong and protective CD8 T-cell responses 
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(Ulmer et al., 1993). Unfortunately, when transferred to non-human primates and humans, 
DNA vaccination protocols failed in inducing optimal cellular and humoral immune 
responses and nowadays the main challenge is how to increase the potency of this vaccination 
strategy (Kutzler and Weiner, 2004). In a recent phase 1 safety and immunogenicity study 
(Graham et al., 2006), a DNA vaccine composed of 4 plasmids encoding Env glycoprotein 
from clades A, B, and C and an HIV-1 Gag-Pol-Nef fusion protein, induced humoral and 
cellular immune responses in the majority of the vaccinated volunteers (Table I). However, 
the detected responses were low in magnitudes and were directed only to the Env constructs. 
With the aim to improve the immunogenicity of the Gag, Pol, and Nef antigens, a new 
product was developed to express the genes on three different plasmids. The new vaccine 
formulation, composed by six plasmids encoding Env A, Env B, Env C, Gag B, Pol B, and 
Nef B , was tested in  a small phase I evaluation trial and resulted in a better immunogenicity 
of the Gag, Pol, and Nef antigens (Catanzaro et al., 2007). Nevertheless, the magnitude of the 
immune response remained low. An overview of these clinical trials is shown in Table I. 
These studies also demonstrated how important could be the phenomenon of immune 
interference in the design of new vaccines. In fact, the insertion of several antigens in the 
same vaccine could be detrimental for the immunogenicity of the entire vaccine. As shown in 
Table I, immune interference is not an issue solely related to DNA vaccines. In fact, also a 
rAd5 vaccine developed by the Vaccine Research Center at the NIH to be combined to the 
DNA vaccine and expressing the fusion protein Gag-Pol resulted to be poorly immunogenic. 
Thus, single component vaccines needs to be evaluated more in deep before the construction 
of multi-antigen vaccines.  
Table I: DNA and Ad5 vaccination in humans (Vaccine Research Center, NIH) 
Delivery Administration Quantity (n of subjects) Antigens T-cells Antibody Endpoint 
       
Phase I dose-escalation study of a multiclade HIV-1 DNA vaccine (Graham, JID, 
2006)   
pl(10), 2mg(5) Env A, B, C Low Low needle-free 
intramuscolar w 0, 4, 8 4mg(20), 8mg(15) Gag-Pol-Nef (B) No No 
Safe 
Immunogenic
       
Phase I evaluation of a six plasmid multiclade HIV-1 DNA vaccine (Catanzaro, 
Vaccine, 2007)   
Env A, B, C Low Low needle-free 
intramuscolar w 0, 4, 8 4mg(14) 
Gag, Pol, Nef (B) Low Low 
Safe 
Immunogenic
       
 19
Phase I dose-escalation study of a multiclade HIV-1 rAd5 vaccine (Catanzaro, JID, 
2006)   
pl(6), 109(10) Env A, B, C Low Low 
intramuscolar w 0 
1010(10), 1011(10) Gag-Pol (B) No No 
Safe 
Immunogenic
 
To date, sparse data on therapeutic vaccination using DNA are available. The first human trial 
using DNA as therapeutic vaccine used DNA env and rev in therapy naïve subjects with CD4 
count > 500. The vaccine resulted to be safe but poorly immunogenic (MacGregor et al., 
1998). Successive studies in HIV-1 infected subjects undergoing HAART, demonstrated a 
better immunogenicity, however responses were never strong and generalized (Hejdeman et 
al., 2004). Recently, a DNA vaccine expressing HIV-1 gag p24/p17 and a string of CTL 
epitopes (pTHr.HIVA®) (Dorrell, 2005; Dorrell et al., 2006) tested on ten patients under 
HAART resulted to be poorly immunogenic. These studies demonstrated that currently used 
DNA vaccination strategies are unable to boost virus specific responses in HIV-1 infected 
individuals.  
Several approaches are underway to enhance the immunogenicity of DNA vaccines. These 
include co-administration of cytokines genes, altering codon bias of the encoded gene, 
changing the cellular localization of the expressed antigen and using different adjuvants. In 
addition, one interesting option to increase the immunogenicity of DNA vaccines is to boost 
the responses with a subsequent vaccination performed with recombinant proteins or 
recombinant viruses, such as orthopoxviruses. 
The co-administration of SIVmac239 Gag and HIV-1 89.6P Env together with the IL2 gene 
produced interesting results in rhesus monkeys challenged with a pathogenic SHIV-89.6P 
(Barouch et al., 2000). After challenge, control animals developed high plasma viral RNA 
levels, depletion of CD4 T lymphocytes and progression to disease. In contrast, seven out of 
eight vaccinated animals had no evidence of disease progression for more than two years after 
challenge. All the vaccinated animals showed a strong virus-specific CTL response and the 
lack of viral control in one animal correlated with escape from CTL recognition (Barouch et 
al., 2002). This DNA cytokine augmented set up constitute a valid example of improvement 
of a DNA based vaccine. 
Viral vectors 
Several viral vectors have been used to develop vaccines against HIV. These include, 
mammalian pox-virus (MVA, NYVAC), Avian pox-virus (ALVAC, Fowlpox), Adenovirus 
(Ad5), Alphavirus, Rhabdovirus (vesicular stomatitis virus), Herpesvirus, and Picornavirus 
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(Robinson, 2002). The viral vectors that have had the most preclinical success and are now in 
a more advanced stage of clinical development are modified vaccinia Ankara (MVA) and 
adenovirus 5 (Ad5). Both viral vectors do not replicate in primate cells and represent ideal 
vectors to be used in immunocompromised populations. Thus, in developed countries, they 
can be used as therapeutic vaccines and in developing countries, they can be used to vaccinate 
people with an unknown HIV status. One potential problem in applying these vectors to 
humans is that their effectiveness can be limited by pre-existing host immunity. In fact, 90% 
of people in developing countries have pre-existing immunity to Ad5 and all people born 
before 1970 have been immunized against smallpox using vaccinia virus. Since variola virus 
the etiologic agent of smallpox is now eradicated and smallpox vaccination will not be 
necessary in the future, the problem of host pre-existing immunity to MVA will probably 
disappear along the time. 
MVA and Ad5 vectors have been often used in a prime-boost strategy in order to boost 
immune responses previously elicited by DNA vaccines. Preclinical trials in monkey models 
performed with recombinant MVA and recombinant Ad5 had promising results. T-cell 
responses rose by prime-boost strategies using DNA and MVA or Ad5 vectors successfully 
controlled pathogenic challenges with the SHIV 89.6P chimera (see Table II). Strong virus 
specific CD8 responses were detected after the administration of the vaccine; with the 
DNA/Ad5 prime-boost combination being the more effective and the MVA/MVA 
combination being the least effective (see Table II and Figure III). Despite major differences 
in the immunogenicity, all the vaccination strategies shown in Table II and Figure III, were 
effective in reducing the viral set point after SHIV-89.6P challenge. The challenge resulted in 
a reduced viral set point in comparison to not vaccinated monkey even when live viral vectors 
were used alone and demonstrated to elicit low immune responses. Thus, measured immune 
responses did not predict the outcome of the challenge. In these trials, immune responses were 
monitored by following the expression of IFN-γ after antigenic stimulation or by tracking the 
epitope specific T-cells with MHC multimer technology. Monkeys were usually typed for the 
Mamu-A*01 MHC allele and immune responses were tracked using Gag-CM9 MHC 
multimer. Despite the lack of correlation between measured immune responses and viral 
control, DNA/IL2 vaccinated monkey lost viral control after escape from specific CD8 
responses (Barouch et al., 2002) and DNA/MVA vaccinated monkeys lost viral control after 
depletion of CD8 T-cells (Robinson and Amara, 2005). Thus, while control of viral 
replication after challenge correlates with the presence of vaccine elicited specific CD8 T-
cells, the capacity to mount such protective response does not correlate with the magnitude of 
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vaccine-elicited CD8 T-cells. Trials including the experimental depletion of T-cell 
subpopulations after vaccine administration but before challenge should be undertaken to 
discover correlates for the efficacy of the vaccines. 
 
Figure III: Patterns of CD8 T-cells specific to the immunodominant Gag-CM9 epitope during vaccination 
and challenge for a DNA/Ad5 vaccine (a) (Shiver et al., 2002), a cytokine augmented DNA vaccine (b) 
(Barouch et al., 2000), and a DNA/MVA vaccine (c) (Amara et al., 2001).  From H.L. Robinson and R.R. 
Amara, Nat Med 2005.  
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Table II: Prime-boost studies in the Rhesus macaque model challenged with SHIV-89.6P 
Model  Delivery Administration Antigens T-cells Antibody Challenge Outcome 
         
Control of a mucosal challenge by a multiprotein DNA/MVA vaccine (Amara, Science 2001)         
Prime► id, im (needle free) w 0, 8 (DNA) 
SIVmac239(Gag, Pol, Vif, Vpx Vpr) 
HIV89.6(Env, Tat, Rev) Low Low Rhesus 
macaque 
Boost► id, im (needle) w 24 (MVA 2x108) SIVmac239(Gag, Pol) HIV 89.6(Env) Strong Low 
m 7, 
intrarectal, 
SHIV-
89.6P 
Reduced 
viral set point 
         
Different patterns of immune responses but similar control of SHIV 89.6 by MVA and DNA/MVA vaccines (Amara, J Virol 2002)     
Prime► id w 0, 8 (MVA 2x108) Low High Rhesus 
macaque Boost► id, im w 24 (MVA 2x108) 
SIVmac239(Gag, Pol) HIV 
89.6(Env) Low High 
m 7, 
intrarectal, 
SHIV-
89.6P 
Reduced 
viral set point 
         
Reduction of a SHIV 89.6P Viremia in Rhesus Monkey by rMVA vaccination (Barouch, J Virol 2001)         
Rhesus 
monkey   im w 0, 4, 21 (MVA 10
8) SIVmac239(Gag, Pol) HIV 89.6(Env) Low No 
w 27, iv, 
SHIV-
89.6P 
Reduced 
viral set point 
         
Replication incompetent Ad5 elicit effective anti-immunodeficiency virus immunity (Shiver, Nature 2002) 
Prime► w 0, 4, 8 (DNA) Low No 
Boost► W 25 (DNA) Medium No 
Reduced 
viral set point 
(3/3) 
Prime► w 0, 6 (MVA) Low No 
Boost► w 32 (MVA) Low No 
Reduced 
viral set point 
(2/3) 
Prime► w 0, 6 (Ad5) Medium No 
Boost► w 32 (Ad5) Strong No 
w 12, iv, 
SHIV-
89.6P 
Reduced 
viral set point 
(3/3) 
Prime► w 0, 4, 8 (DNA) Medium No 
Boost► w 32 (MVA) Strong No 
Reduced 
viral set point 
(1/3) 
Prime► w 0, 4, 8 (DNA) Low No 
Rhesus 
macaque 
monkey 
Boost► 
im 
w 32 (Ad5) 
SIVmac239(Gag) 
Very Strong No 
w 6, iv, 
SHIV-
89.6P Reduced 
viral set point 
(3/3) 
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The relevance of the animal and challenge model used in these studies is not firmly 
established. The SHIV-89.6P chimera expresses a CXCR4 specific HIV envelope and after 
infection causes a dramatic decrease of total CD4 T-cell. AIDS develops in almost all the 
infected animals within six months from infection. This aggressive virus does not resemble 
HIV-1 that soon after infection establishes a long phase of latency that last for years before 
the first manifestations of AIDS related symptoms. Intriguingly, this aggressive virus seems 
easier to control by vaccination and studies conducted with the less aggressive CCR5 
dependent viruses SIVmac239 and SIVmac251 resulted in a modest reduction of the viral set 
point (Aandahl et al., 2003; Horton et al., 2002; Vogel et al., 2003). In addition, recent studies 
addressing the influence of MHC class I haplotype on vaccine mediated protection, 
demonstrated that the expression of the MHC class I allele Mamu-A*01 was associated with a 
particularly efficient control of the SHIV-89.6P (Seaman et al., 2005). The same has been 
shown for vaccination and challenge studies using the less virulent SIVmac. 
To overcome these problems Letvin et al. (Letvin et al., 2006) immunized monkeys that do 
not expressed Mamu-A*01 alleles and performed a challenge using the less virulent SIVmac 
strain. In addition, after challenge, monkeys were followed for more than three years to 
evaluate the long-term effect of the vaccine. DNA/Ad5 vaccinated monkeys showed only a 
limited reduction of the viral set point after challenge but the long-term follow up revealed 
significant difference in survival associated with the preservation of central memory CD4 T-
cells. This study constitutes the base for further studies in monkeys and suggests a possible 
correlate of protection that can be analyzed in humans. 
In summary, two main problems affect studies performed in monkeys: the relevance of the 
animal, and challenge model and the absence of a correlate of protection. In addition, it is not 
evident that these issues will be solved in the recent future. Therefore, it will be important to 
translate as soon as possible this vaccination protocols in clinical trials in order to establish 
their relevance for human beings. 
 
 MVA and Ad5 carrying different HIV-1 antigens have been already used in phase I and II 
clinical trials. Both vectors were safe and able to elicit immune responses to the inserted 
antigens. However, since efficacy studies in healthy subject require a large number of 
individuals and a long term follow up, at present time, no data exist on the efficacy of this 
vector as prophylactic vaccines. ALVAC vCP1521 vector is now in a more advanced stage of 
development. In October 2003, Sanofi Pasteur started a large phase III clinical trial to 
evaluate the efficacy of a prime/boost vaccine strategy employing an ALVAC vCP1521 (env 
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B, E; gag/pol) and the AIDSVAX B/E (protein env B, E). The placebo controlled double-
blinded study will enroll 16,000 volunteers in Thailand and will end by June 2009. 
MVA, Ad5 and ALVAC have been used in therapeutic vaccine settings. The therapeutic 
setting can provide information on efficacy even with a limited number of study subjects.  
However, despite safety and immunogenicity have been demonstrated, no indication of 
efficacy has been reported to date. 
Vaccination using MVA 
The interesting data obtained in the monkey model fostered the use of MVA as vaccine vector 
in humans. MVA does not replicate in most mammalian cells and since the block in the 
replication cycle is at a late stage of morphogenesis, early and late gene expression is not 
impaired. This allows for a good expression of the inserted genes and for good safety 
characteristics. 
The first report of a Phase I clinical trial using a recombinant MVA expressing an HIV-1 
derived antigen is the main subject of this thesis (Cosma et al., 2003). Briefly, the vaccination 
of 10 chronically HIV-1 infected subjects with a MVA-HIV-1LAI-nef vector resulted to be 
safe and immunogenic. Interestingly, elicited immune responses were mainly mediated by 
CD4 T-cells. This study provided also valuable information upon the use of MVA as an 
alternative vaccine against smallpox in HIV-1 infected patients under HAART (Cosma et al., 
2007). 
Following this first report in HIV-1 infected individuals, the group of T. Hanke and A. J. 
McMichael demonstrated the capacity of MVA to induce HIV-1 specific responses in healthy 
subjects (Mwau et al., 2004). In this case, the MVA vector was expressing a consensus HIV-1 
clade A Gag p24/p17 proteins fused to a string of clade A CTL epitopes (Hanke et al., 2002). 
These pioneering studies were followed by other clinical trial that showed the good 
immunogenicity of MVA as a vaccine against HIV-1 (Dorrell et al., 2006; Goonetilleke et al., 
2006; Harrer et al., 2005).  
Vaccines to cellular proteins 
In 1995, Stott et al. (Stott and Almond, 1995) showed that monkeys vaccinated with 
inactivated SIV grown on human cells and challenged with the same virus were successful 
protected. When the challenge was performed with SIV grown on monkeys’ cells no 
protection was observed. At that time, it was not clear if protection was mediated by allo-
specific or xeno-specific humoral immune response. However, it was clear that cellular 
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molecules incorporated into virions played a role in the protection mechanism. Since, this 
vaccination strategy succeeded in achieving full protection, further investigations should be 
undertaken now that new technologies to dissect immune responses are available. 
Host derived proteins are selectively incorporated into viral particles (Esser et al., 2001) and 
can confer new functions and new antigenic properties to the virus. For instance, ICAM-1, 
HLA class II and CD28 molecule accelerate the kinetic of viral entry by interacting with their 
corresponding counter-receptors displayed on the target cells (Giguere et al., 2005; Tremblay 
et al., 1998). The analysis of these molecules might be useful in the design of vaccines that 
can better mimic the envelope of the virus or can target important step in the virus life cycle. 
 
In 1999, we characterized the effect of the incorporation of HLA class I molecules into viral 
particles (Cosma et al., 1999). The study addressed in particular the role of the incorporation 
of the HLA Cw4 allele into CXCR4 dependent viruses. The incorporation of HLA-class I 
Cw4 alleles increased the infectivity of newly formed viral particle changing the 
conformation of the Envelope protein. As shown in Figure IV, the incorporation of HLA Cw4 
into LAI and Bru virions increased the capacity of these viruses in entering an indicator CD4+ 
cell line. Similar results were observed upon incorporation of HLA Cw4 into primary isolates. 
The incorporation of HLA Cw4 had no effect on the NL4-3 and NDK viral strain.  
 
Figure IV: Effects of HLA Cw4 expression on infectivity. Viruses generated from HLA Cw4 negative 
(open symbols) and positive (closed symbol) cells collected at the peak of infection were added to Hela-
CD4-LTR-LacZ P4 indicator cells and efficiency of infection was measured by colorimetric determination 
of β-gal activity in cell extracts. pg/ml of virus added to assay are indicated on the x axis. β-gal activity in 
term of optical density is shown in the y axis. The different strain of HIV tested are shown on the top of 
each graph. 
The observed increase in infectivity was associated with conformational changes in regions 
responsible for the viral tropism, such as the V3 loop and the epitopes normally induced by 
the interaction with the CD4 receptor. These changes were probably induced by direct 
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interaction of the Envelope protein and the HLA Cw4 molecule on the surface of the virions. 
In fact, we were able to co-precipitate the two molecules from the surface of actively HIV-
1LAI producing cells (Figure V). 
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Figure V: Western blot analysis of immunoprecipitates from HIV-1LAI infected HLA-Cw4 expressing cells.  
Cell expressing HLA-Cw4 or not (as indicated at the top) were infected with HIV-1LAI (LAI+) or left 
untreated (LAI-). Then, lysates were immunoprecipitated with an antibody (P4D10)  recognising the V3 
loop of the envelope protein or an antibody (L31) recognising the HLA-C molecules (in green). 
Immunoprecipitated material was separated using SDS-PAGE and then transferred to a nitrocellulose 
membrane that was probed with the antibodies P4D10 and L31 (in red). Moleular weights are shown on 
the left. 
These data indicate that a host derived molecule is able to modulate the conformation of the 
HIV-1 Envelope protein (Figure VI). These modifications include epitopes important for 
antibody specific virus neutralization and can unmask cryptic epitopes. Thus, complex of 
Envelope and HLA-Cw4 molecules can be used to build protein or cellular vaccines with 
different and may be better antigenic properties. It is also possible that the observation of Stott 
et al. may be better explained in terms of a different capacity of human and monkey host 
derived molecules to interact with the SIV Envelope. 
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Figure VI: ICAM-1 enhance the infectivity of the HIV-1 viral particle via the interaction with its natural 
ligand expressed on the target cell. HLA-Cw4 acts in cis and changes the conformation of the Envelope 
protein on the viral particle. We hypothesized that these conformational changes allow a better interaction 
with the CD4 receptor and the CXCR4 co-receptor on the target cell. This conformational change can be 
used to formulate new antibody based vaccines. 
Correlates of protection 
To evaluate AIDS vaccine formulations in humans is necessary to have indications about 
possible correlates of protection. Unfortunately, at present time, no clear correlates of 
protection or viral control exist and animal models did not provide this information. 
One possibility to find correlates of protection is the study of humans that can naturally 
control infection or remain apparently uninfected despite repeatedly contacts with the virus. 
Long Term Non-Progressor 
Long term non-progrssor (LTNP) represent 1 to 5 % of the HIV-1 infected individuals and are 
characterized by a documented HIV-1 infection for more than seven years, stable and high 
total CD4 counts, usually more than 600 cell/mm3, low levels of viremia in peripheral blood, 
no history of anti-retroviral therapy and no symptoms of AIDS disease. The genetic 
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background of the host, the characteristic of the virus, a peculiar host immune response or a 
combination of all these factors may be responsible for the non-progressive status. 
Polymorphisms in the genetic background of the host responsible of decreased susceptibility 
to infection and delayed progression to AIDS include the HIV co-receptors CCR5 and CCR2 
(Dragic et al., 1996; Hogan and Hammer, 2001; Lee et al., 1998; Quillent et al., 1998), the 
chemokine SDF-1 (Meyer et al., 1999) and the HLA-B57 allele (Migueles et al., 2000). 
In the virus genome, mutations and deletion in the regulatory gene nef have been clearly 
associated with the non-progressive status (Catucci et al., 2000).  
While the genetic markers in the host and the virus have been clearly associated with a slow 
progression to AIDS, immunological markers are more difficult to track and up to now, we do 
not have clear evidences for immunological markers of protection or slow progression. 
However, the example of LTNP demonstrates that control of viral replication by the immune 
system in the context of the natural course of the disease is possible. The analysis of the anti-
HIV immune response in LTNP, chronically HIV infected individuals under HAART and 
individuals with progressive disease highlighted some possible correlates of protection and 
some possible immunological mechanisms of viral control. HIV specific CD4 T-cell plays a 
key role in this scenario. Indeed, proliferative capacity (Rosenberg et al., 1997), IL2 (Harari et 
al., 2004) and IFN-γ (Pitcher et al., 1999) production were preferentially observed in HIV-
specific CD4 T-cells derived from LTNP. Interestingly, better proliferative capacity and 
higher perforin expression was detected in HIV-specific CD8 T-cells derived from LTNP 
(Migueles et al., 2002). The capacity of HIV-specific CD8 T-cells to proliferate was 
associated with the presence of HIV-specific CD8 T-cells able to produce simultaneously 
IFN-γ and IL-2 (Zimmerli et al., 2005). Despite the phenotype of proliferating IFN-γ/IL-2 
secreting CD8 T-cells represent an attractive marker of slow progression to AIDS, a similar 
population has been found in 30% - 40% of subjects successfully treated with HAART 
(Harari et al., 2006). Therefore, the preserved capacity to proliferate may merely represent a 
marker for a not yet compromised immune system. All this observations suggest that the 
immune system may be able to control viral replication. More recently, Betts et al. (Betts et 
al., 2006), observed that polyfunctional CD8 T-cell were preferentially observed in LTNP. 
Polyfunctionality was intended as simultaneous production/expression of CD107, IFN-γ, 
MIP-1β, IL-2, and TNF-α and/or CD107, IFN-γ, MIP-1β, and TNF-α. In contrast with 
previous studies expression of IL-2 was not associated with the LTNP status and significant 
differences between LTNP and progressor were mainly observed in polyfunctional CD8 T-
cells lacking IL-2 expression. 
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In summary, from all these studies is difficult to define clear protection markers, often each 
study is focalized only on one aspect of the immune response and the characteristics of the 
cohorts of patients differs from one study to another. In addition some studies are based on a 
limited number of subjects and conclusions could be biased by sampling problems. 
Seronegative subjects exposed to HIV 
Exposure to HIV-1 does not always lead to infection as observed in person in high-risk group 
who are not infected despite frequent exposure to HIV-1. HIV-1 exposed seronegative (ESN) 
individuals are mostly found between long-term sexual partners of HIV-1 infected individuals 
(serodiscordant couples) and commercial sex workers suggesting that the frequency of the 
exposure is an important factor to be considered. This observation also support the idea that 
acquired factors are likely involved in this resistance. As for the LTNP, several 
immunological mechanisms and markers have been studied in ESN. Since HIV is mainly 
sexually transmitted and the first contact with the host is at the level of the genital mucosa, the 
presence of HIV-specific mucosal IgA in HIV-1 negative partners of serodiscordant couples 
(Mazzoli et al., 1997) represents one important mechanism of protection involving the 
humoral immunity. Interestingly, when we purified IgA from ESN, we observed a clear 
neutralizing activity in 5 out of 15 subjects (Mazzoli et al., 1999). Of note, the neutralization 
assay was performed using HIV-1 primary isolates. These studies demonstrate that an HIV-
specific immune response is present in HIV-1 negative and highly exposed subjects. 
In our studies focused on ESN individuals, we also observed the presence of anti-HLA class I 
antibodies in seronegative injection drug users at risk for HIV exposure (Beretta et al., 1996b) 
and HIV-1 negative partners of serodiscordant couples (Beretta et al., 1996a; Lopalco et al., 
2000). An immune response against cellular targets highlight the importance of cellular 
proteins incorporated into virions and the possible use of this molecules in vaccine 
formulations (see also “Vaccines to cellular proteins”). 
On the side of the cellular immunity HIV-1 specific CD8 and CD4 T-cells have been found in 
several cohort of female sex workers (Alimonti et al., 2006; Alimonti et al., 2005; Fowke et 
al., 2000; Jennes et al., 2004), suggesting a possible role of the cellular immune response in 
protection from infection. However, we cannot exclude an antibody mediated protective role 
at the mucosal site and a cellular immune response simply reflecting the contact with the virus. 
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Summary by points of the main challenges for an AIDS vaccine 
Despite our knowledge of HIV-1 and its interaction with the host is increasing, the hope to 
have a vaccine against HIV-1 in a short term is not foreseen. Here are summarized a series of 
important challenges that we have to face to find an effective vaccine against HIV-1.  
1. Neutralizing antibodies 
a. Conserved epitopes are hidden by variable regions and glycosylation 
2. Integrated proviral DNA 
a. Has a long half-life 
b. Forms an archive of all the virus infecting the host over the time 
c. Can be reactivated to produce infective virions 
d. Viral protein are not expressed in the latent phase 
3. HIV genome is high variable 
a. There are 12 known subtypes 
b. Regional vaccines might be necessary 
c. Escape mutants are constantly generated 
4. Lack of a suitable animal model 
5. Lack of a clear correlate of protection in humans 
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Materials and Methods 
Reagent Setup 
• Culture medium: prepare RPMI 1640 medium (Cambrex, cat.no. BE12-702F/U1) 
supplemented with 10% heat-inactivated FCS (Biochrom AG, cat.no. S0115) and 1% 
PenStrep (Cambrex, cat.no. DE17-602E) -> lab name is RPMI-10 
• Live/Dead staining solution: Used for to count cells, Trypan Blue (Gibco, Invitrogen, 
Cat.no. 15250-061) 
• Costimulating antibodies (coAbs): CD28 pure (BD, cat.no. 340975), CD49 pure 
(BD, cat.no. 340976)  
• Peptide pools: use 2μg/ml peptide in the total volume of 200μl (after the addition of 
the BFA) 
• Negative & positive control: negative control is only RPMI-10, positive control is 
with PMA + Ionomycin (PMA+I) 
• PMA: Phorbol 12-myrstate 13-acetate (Sigma, cat.no. P-8139), prepare a stock 
solution with a concentration of 0.1mg/ml in DMSO (Sigma, cat.no. D2650), store 
small single-use-aliquots at -20°C 
• Ionomycin: (Sigma, cat.no. I-0634), prepare a stock solution with a concentration of 
0.5 mg/ml in EtOH, store small single-use-aliquots at -20°C 
• BFA: Brefeldin A (Sigma, cat.no. B-7651), prepare a stock solution with a 
concentration of 5mg/ml in DMSO, store small single-use-aliquots at -20°C  
• EMA: Ethidium monoazide bromide (Invitrogen, Molecular Probe, cat.no. E-1374), 
live/dead discriminator, prepare a stock solution with a concentration of 2mg/ml in 
DMFA, store at -20°C for long time, once thawed keep at 4°C 
• FACS buffer: (BD Pharmingen Stain Buffer 0,2% BSA, 0,09% Na Azide in DPBS, 
cat.no. 554657)  
• A3.01 cells: Centre for AIDS Reagents (EU Programme EVA/AVIP), ARP098, 
Human CD4+ T Cell line 
• MVA-gfp: single-use aliquot (115µl), 5*107 IU/ml, stored at -80°C -> the amount of 
MVA-gfp has to be determined doing a titration for each viral preparation in order to 
obtain between 200 and 400 Gfp expressing cells 
• PBS: phosphate buffered saline 
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• Dianisidine solution: Prepare a saturated solution of O-Dianisidine (D9143, Sigma) 
in EtOH, vortex al least 1’, let stand at least 1h at room temperature protected by light, 
vortex, spin down. You can store this solution ten days at 4°C. Always vortex before 
use. 
Immune-staining of MVA infected cells 
The immune-staining is performed on cells forming a monolayer, such as CEF or HeLa. It is 
usually performed in 6 wells/plates on confluent cells 
Wash the cells 1X PBS 
• Fix with Acetone/Methanol (1:1) 5’ room temperature 
2X wash with PBS 
• I Ab in PBS 3%FCS 1h room temperature (L31 1/500, P4D10 1/250) 
2X wash in PBS 3%FCS 
• II Ab goat anti mouse HRP (1/500) in PBS 3%FCS 45’ room temperature 
3X wash in PBS 
• Add substrate (O-Dian.) solution 
Prepare substrate solution just before adding to the cells: 
add 200µl O-Dianisidine solution and 10µl H2O2 to 10ml of PBS 
Wait until plaques are visible and the background in the negative control remain clear. Then, 
simply wash away the O-Dianisidine solution with PBS. 
Let dry the stained cells. 
Western Blot analysis of the expression of the Nef protein delivered 
by the recombinant vector MVA-nef 
1) Infection of target cells with MVA-nef 
1.5 * 106 B-LCL has to be infected with 10 pfu MVA/cell in a total volume of 225 μl of 
complete media. Perform the incubation in a 48 well plate. 
Sample list: 
B-LCL + mock infection 
B-LCL + MVA wt 
B-LCL + MVA nef (laboratory production) 
B-LCL + MVA nef (GMP production) 
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 2 hours, 37°C 
1 wash 
Transfer the cells in a 6 wells plate in a total 3 ml volume. 
overnight at 37° 
Take all the cells; 1500 rpm for 5’ 
Add 150μl of 1% NP40 in PBS (Cold) 
Keep on ice for 20’ 
14000 rpm, 2' 
Take the supernatant and add 37.5μl of SB5x 
Boil 5’ at 95°C, 
 
2) Analyze sample in SDS-PAGE and Western Blot 
3) Staining of the Western Blot 
The following buffer was used for the incubations: 5% BSA, 0.05%Tween in PBS (BSA-T-
PBS). The washing steps were performed in the same buffer without BSA (T-PBS). 
After the transfer, the nitrocellulose membrane is dried over-night. 
The nitrocellulose membrane is carefully immerged in the T-PBS buffer. 
3 wash with T-PBS 
Overcoating: 1h in BSA-T-PBS 
3 wash with PBS 
I Ab 2hours 3D6 (1/200) 
3x5’ washes in T-PBS 
II Ab Goat anti mouse HRP 1 hour (1/2000) 
8x5’ washes 
Develop using Lumi Light 
Intracellular cytokine staining 
Peripheral blood was collected in heparin and processed using standard Ficoll (Biochrom, 
Berlin, German) density centrifugation. Lymphocytes were adjusted to 6,6 x 106 cells/ml in 
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RPMI 1640 (Biochrom), 10% FCS, 1% antibiotics, 1,3 μg/ml anti CD28 and 1,3 μg/ml anti 
CD49d costimulatory antibodies (Becton Dickinson, Heidelberg, Germany). Then, 150 μl of 
cell suspension was plated in a 96 well plate together with peptides and left for 1 hour at 37°C 
in a humidified 5% CO2 atmosphere. Brefeldin A (Sigma, Taufkirchen, Germany) was added 
to the cell suspension to a final concentration of 10 μg/ml and cells were subsequently 
incubated for 4 hours. Stimulated cells were incubated the photoreactive fluorescent label 
ethidium monoazide (EMA; Molecular Probe, Leiden, Netherlands) used as viability probe. 
Antibodies to surface antigens were added and incubation carried out on ice for 30 min. Then, 
cells were fixed and permeabilized, before adding antibody to the intracellular markers. Cells 
were analysed using a FACS Calibur (Becton Dickinson), a LSRII (Becton Dickinson) or a 
CYAN (Dako Cytomation) flow cytometer. The workflow for the intracellular cytokine 
staining procedure is shown in Figure VII. Four different sets of HIV peptides were used to 
stimulate lymphocytes: (i) 20-mer peptides overlapping by 10 amino acids corresponding to 
HIV strain LAI spanning the Nef, Tat and Rev proteins, (ii) 20-mer peptides overlapping by 
10 amino acids corresponding to HIV strain SF2 spanning the p24 protein, (iii) 15-mer 
overlapping by 5 amino acids corresponding to HIV strain SF2 spanning the p17 protein, (iv) 
optimally defined epitopes from 8 to 11 amino acid in length derived from HIV-LAI Nef as 
described in the Los Alamos Molecular Immunology Database (Korber B., 2001), referred 
here as Nef CD8 Opt. The final concentration of each individual peptide was 0,4 μg/106 cells 
for all the experiments described. Alternatively, PBMC were infected with MVA in order to 
analyze vaccinia specific immune responses. 
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Figure VII: Example of workflow for the IFN-γ-based intracellular cytokine staining 
Detailed protocol for the peptide stimulation of PBMC 
Warm up the RPMI-10 to 37°C! 
Use: 1 x106 cells/150µl RPMI-10 + coAbs for each experimental sample (Exp) 
         0.5 x106 cells/150µl RPMI-10 + coAbs for each compensation sample (Cmp) 
1) RPMI-10 + coAbs: 
Prepare always for 2-3 samples more than needed in a 50 ml Falcon tube 
 
 
 
 
 
Resuspend the samples in RPMI-10 + coAbs and distribute 150μl in each well  
2) Peptide pools (Antigens): 
 RPMI-10 (µl) CD28 (µl) CD49d (µl) 
1   sample 150 0.2 0.2 
25 samples 3750 5 5 
40 samples 6000 8 8 
 36
Use 2μg/ml peptide in the final 200μl (the total volume will be 200μl after the addition of the 
BFA) 
Prepare PMA+I working solution: 20μl PMA stock solution + 1980μl PBS 
     20μl I stock solution        +   180μl PBS 
Pipette PMA and I with 100µl-filtered tips 
For 6 individuals: 
 
 
 
 
 
 
 
 
 
 
Distribute 10μl of peptide pools in each experimental sample 
 1 hour at 37°C 
3) BFA:  
Prepare working solution: 20μl BFA stock solution + 180μl PBS  
Mix 192μl BFA working solution with 2200μl RPMI-10 
Add 50μl/well (don’t mix) 
 4 hours at 37°C 
4) Stopping the stimulation:  
Cover the edges of the plate with parafilm and store over night at 4°C, protected by light. 
On the next day start the staining following the appropriate protocol. 
Detailed protocol for the MVA stimulation of PBMC 
4x106 frozen cells are used for each determination (-Ctrl and Sample) 
Keep RPMI-10 at room temperature before starting the experiment 
 peptide (µl) RPMI-10 (µl) 
Neg Ctrl 0 60 
Nef 4.8 55.2 
Nef Opt 21.3 38.7 
Tat 2.6 57.4 
Rev 2.9 57.1 
p17 3.1 56.9 
p24 5.3 54.7 
PMA + I 22.5 + 18 19.5 
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1) First day: MVA infection 
Thaw the cells 
2 wash in RPMI-10 (use 50 ml Falcon tube) {MVA preparation} 
Resuspend cells in 400 μl RPMI-10 (always in the same 50 ml Falcon tube) 
Take out 50 μl as Neg Ctrl and 50 μl to be infected with MVA;  
 
 
0.5x106 cells/well 
 
Plate them in a 96 well/plate flat bottom where the MVA (2.5x106 pfu; 5pfu/cell) was already 
plated. Mix well when adding the cells. Fill with PBS the wells around the samples. 
Add 300 μl RPMI-10 to the 50 ml Falcon tube and leave the tubes in a slant position with the 
cap loosened in the incubator overnight 
Leave RPMI-10 out of the fridge for the next day 
2) MVA preparation 
Thaw MVA (Example: MVA_F6 583 CEF 2.1x109 pfu/ml) 
Vortex 30’’, put on ice, vortex, ice, vortex, ice 
Use 1.2 μl MVA + 8.8 μl RPMI-10/sample 
Plate in the 96 well/plate flat bottom before adding the cells 
Example: 
 #1 #2 #3 #4 #5 
#1 #2 #3 #4 #5 
3) Second day: stimulation 
Infected cells in 96 well/plate flat bottom: 
Add 150 μl RPMI-10 (r.t.) and transfer cells to a 96 well/plate round bottom 
2 wash with RPMI-10 (r.t.) 
Leave the {pellet} 
Cells in 50 ml Falcon: 
Add 5 ml RPMI-10 (r.t.) 
1500 rpm, 5’, 21˚C, discard media 
Add 300 μl of RPMI-10 + 0.4 μl (0.4 μg) CD28 and CD49d Abs 
- Ctrl MVA 
- Ctrl 
MVA 
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Add the cells to the {pellet}; 150 μl for the –Ctrl well and 150 μl for the MVA infected well 
(1.5x106 cells/well) 
Follow the standard ICS protocol 
Detailed protocol for the IFN-γ-based intracellular cytokine staining 
Resuspend the cells with a multi-channel pipette. 
1500 rpm, 5’, 4°C 
Prepare EMA solution: 1μl in 1ml of FACS buffer (0,5% BSA, 0,02% NaAzide in PBS). 
Add 50μl EMA sol. to each well 
 20’ on ice, in the dark 
 10’ on ice, to strong light 
Add 150μl FACS buffer, 1500 rpm, 5’, 4°C 
2 wash with 200μl FACS buffer, 1500 rpm, 5’, 4°C 
Add 50μl FACS buffer and transfer the cell suspension to a 96 well plate were the antibodies 
to cell surface markers have been already plated. 
Anti CD8 PE 2μl/50μl test X42 samples 84μl + 
Anti CD4 PerCP 2μl/50μl test  84μl + 
Anti CD3 APC 0,5μl/50μl test  21μl +  
  FACS buffer 231μl = 
   420μl  
Distribute 10μl of antibodies dilution in each well. 
 30’ on ice, in the dark 
Add 150μl FACS buffer, 1500 rpm, 5’, 4°C 
2 wash with 200μl FACS buffer, 1500 rpm, 5’, 4°C 
Add 200μl of 1X FACS Lysing sol (resuspend well!) 
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 10’ room temperature, in the dark 
1 wash with 200μl FACS buffer, 1800 rpm, 5’, room temperature 
Add 100μl of 1X Permeabilization sol (resuspend well!) 
 10’ room temperature, in the dark 
Add 100μl FACS buffer, 1800 rpm, 5’, room temperature 
1 wash with 200μl FACS buffer, 1800 rpm, 5’, room temperature 
Add 50μl FACS buffer and transfer the cell suspension to a 96 well plate were the antibodies 
to intracellular markers have been already plated. 
IgG2a FITC 0,25μl/50μl test X6 samples 1,5μl + 58,5μl   
Anti IFNγ FITC 2μl/50μl test X38 samples 76μl + 304μl 
 45’ room temperature, in the dark 
Add 150μl FACS buffer, 1800 rpm, 5’, room temperature 
1 wash with 200μl FACS buffer, 1800 rpm, 5’, room temperature 
Fix the cells with 1% Paraformaldhyeide in PBS 400μl/sample 
Detailed protocol for the IFN-γ/IL-2/CD154 intracellular cytokine staining 
Resuspend the cells, 1600 rpm, 5’, 4°C, discard the supernatant (SN) 
1) EMA staining: 
Prepare working solution: 1μl EMA stock solution in 1ml of FACS buffer  
Resuspend the cells in 50μl/well 
 20’ on ice, in the dark 
             10’ on ice, to strong light 
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Add 150μl FACS buffer, 1600 rpm, 5’, 4°C, discard the SN 
2x wash with 200μl FACS buffer, 1600 rpm, 5’, 4°C, discard the SN 
2) Surface staining: 
Compensation antibodies: 
 (µl) FACS buffer (µl) total (µl) Position 
Voltage Set Up 0 20 20 A 1 
No Abs Ctrl 0 20 20 A 2 
CD8 FITC 4 16 20 A 3 
CD8 PE 2 18 20 A 4 
CD4 PerCP 5 15 20 A 5 
CD8 PacB 2.5 17.5 20 A 6 
CD8 APC 0.5 19.5 20 A 7 
CD3 PE-Cy7 0 20 20 A 8 
 
Surface staining antibody mix: 
for 1 sample (µl) 
CD4 PerCP 5 
CD8 PacB 2.5 
FACS buffer  12.5 
total 20 
the Surface staining antibody mix at 12000 rpm, 3’, 4°C -> transfer the SN to a new 
Eppendorf 
Distribute 20μl of Surface staining antibody mix in the appropriate wells 
Resuspend the cells in 50μl FACS buffer and transfer the cell suspension to the prepared plate 
where the antibodies to cell surface markers have been already plated. 
 30’ on ice, in the dark 
Add 150μl FACS buffer, 1600 rpm, 5’, 4°C, discard the SN 
2x wash with 200μl FACS buffer, 1600 rpm, 5’, 4°C, discard the SN 
3) Fixation & Permeabilization: 
Resuspend well in 100μl Cytofix/Cytoperm reagent 
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 20’ on ice, in the dark 
Add 100μl Perm/Wash buffer, 1800 rpm, 5’, 4°C, discard the SN 
3x wash with 200μl Perm/Wash buffer, 1800 rpm, 5’, 4°C, discard the SN 
4) Intracellular staining: 
Compensation antibodies: 
 (µl) FACS buffer (µl) total (µl) Position 
Voltage Set Up 0 30 30 A 1 
No Abs Ctrl 0 30 30 A 2 
CD8 FITC 0 30 30 A 3 
CD8 PE 0 30 30 A 4 
CD4 PerCP 0 30 30 A 5 
CD8 PacB 0 30 30 A 6 
CD8 APC 0 30 30 A 7 
CD3 PE-Cy7 2 28 30 A 8 
 
 
Intracellular staining antibody mix Effector panel: 
 
 
 
 
 
the Intracellular staining antibody mix at 12000 rpm, 3’, 4°C -> transfer the SN to a new 
Eppendorf 
Distribute 30μl of Intracellular staining antibody mix in in the appropriate wells  
Resuspend the cells in 50μl Perm/Wash buffer and transfer the cell suspension to the prepared 
plate where the antibodies to intracellular markers have been already plated. 
 
for 1 sample (µl) 
IFNγ FITC 13 
CD154 PE 10 
IL2 APC 5 
CD3 PE-Cy7 2 
FACS buffer 0 
total 30 
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 30’ on ice, in the dark 
Add 150μl Perm/Wash buffer, 1800 rpm, 5’, 4°C, discard the SN 
2x wash with 200μl Perm/Wash buffer, 1800 rpm, 5’, 4°C, discard the SN 
5) Acquisiton: 
Acquisition with CYAN and LSRII: 
Resuspend the samples in 350μl FACS buffer in 1ml titer-tubes 
Vortex 
Acquire all 
Acquisition with HTS at LSRII: 
Resuspend in 200µl FACS buffer in a 96well plate V-bottomed 
After each individual fill 3 washing wells with FACS flow solution 
loader settings:  
 
 
 
 
 
 
 
 
Plate cheme: 
experimental sample (Exp) 
compensation sample (Cmp) 
washing wells (wash)       
      Cmp ---------------------------------------------------------------------> 
Voltage 
Set Up 
No Abs 
Ctrl 
CD8 
FITC 
CD8 
PE 
CD4 
PerCP 
CD8 
PacB 
CD8 
APC 
CD3 
PECy7 
 wash wash wash 
Exp 
ID1 
Exp 
ID1 
Exp 
ID1 
Exp 
ID1 
Exp 
ID1 
Exp 
ID1 
Exp 
ID1 
Exp 
ID1 
 wash wash wash 
Exp 
ID2 
Exp 
ID2 
Exp 
ID2 
Exp 
ID2 
Exp 
ID2 
Exp 
ID2 
Exp 
ID2 
Exp 
ID2 
 wash wash wash 
 Set Up Samples Washes 
Sample Flow Rate (µl/sec) 1 2.5 3 
Sample Volume (µl) 150 150 200 
Mixing Volume (µl) 100 100 100 
Mixing Speed (µl/sec) 150 150 200 
Number of Mixes 5 5 0 
Wash Volume (µl) 800 800 800 
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Exp 
ID3 
Exp 
ID3 
Exp 
ID3 
Exp 
ID3 
Exp 
ID3 
Exp 
ID3 
Exp 
ID3 
Exp 
ID3 
 wash wash wash 
Exp 
ID4 
Exp 
ID4 
Exp 
ID4 
Exp 
ID4 
Exp 
ID4 
Exp 
ID4 
Exp 
ID4 
Exp 
ID4 
 wash wash wash 
 
CYAN setting: 
 
 
 44
 
 45
LSRII setting: 
 
FSC setting may change after the regular BD service 
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MVA-gfp neutralization assay 
The MVA-gfp neutralization assay was modified from its original description (Cosma et al., 
2004). Briefly, heat inactivated sera were incubated with the MVA-gfp (multiplicity of 
infection of 0.1) for one hour at 37°C. Then, 0.5 x 106 A3.01 were added and the incubation 
carried out for two more hours in the same conditions. Cells were washed in RPMI-10, 
transferred in 96 well flat-bottom tissue culture plate and kept overnight at 37°C. Then, cells 
were fixed in 1% paraformaldeyde. The percentage of MVA infected A3.01 was evaluated by 
measuring Gfp expression in a FACScalibur (Becton Dickinson) or CYAN ADP (Dako 
Cytomation). For each sample, 100,000 living cells were acquired. Representative pseudo-
color dot plots are shown in Figure VIII.  Five dilutions (1:16 to 1:10,000) were tested for 
each sample to obtain trend lines of percentages of neutralization and units of area under the 
curve (AUC) were calculated using GraphPad Prism version 4.03 (San Diego, California, 
USA). 
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Figure VIII: MVA-gfp neutralization assay. Representative pseudo-color dot plots of a typical MVA-gfp 
neutralization assay. A negative control, a positive control and three dilutions of a preparation of 
neutralizing vaccinia virus immunoglobulin (VIG) are shown 
Detailed protocol for the MVA-nef neutralization assay 
1 day before starting seed A3.01 cells to a density of 1x106/ml in 20ml of RPMI-10 
1) Preparation of the human sera: 
Heat inactivation: 10µl sera in a Eppendorf tube 
   Heat inactivation 30’ at 56°C 
   max speed, 2’, 21 °C 
2) Preparation of MVA-gfp: 
Thaw MVA-gfp  
Vortex 3x for 1’, keep on ice in between 
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For one plate: use 100 µl MVA-gfp + 2400 µl RPMI-10 
Vortex 
3) Preparation of the plate:  
Fill the wells with RPMI-10 according to the scheme, fill the wells around with 100µl PBS 
PBS 40µl 40µl 40µl 40µl 40µl PBS PBS PBS PBS PBS PBS 
PBS 40µl 40µl 40µl 40µl 40µl 45µl 40µl 40µl 40µl 40µl PBS 
PBS 45µl 40µl 40µl 40µl 40µl 45µl 40µl 40µl 40µl 40µl PBS 
PBS 45µl 40µl 40µl 40µl 40µl 45µl 40µl 40µl 40µl 40µl PBS 
PBS 45µl 40µl 40µl 40µl 40µl 45µl 40µl 40µl 40µl 40µl PBS 
PBS 45µl 40µl 40µl 40µl 40µl 45µl 40µl 40µl 40µl 40µl PBS 
PBS 45µl 40µl 40µl 40µl 40µl 45µl 40µl 40µl 40µl 40µl PBS 
PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
 
4) Sera dilution: 
Add 5µl sera to the appropriate wells and perform 1/5 dilutions 
   
                      10μl     10μl    10μl     10μl       10μl 
  
5) Plating the MVA-gfp & NegCtrl: 
Add 25µl of diluted MVA-gfp (vortex before adding) to the appropriate wells, for the NegCtrl 
wells add only 25µl RPMI-10           
 NegCtrl NegCtrl NegCtrl NegCtrl NegCtrl       
 MVA MVA MVA MVA MVA MVA MVA MVA MVA MVA  
 MVA MVA MVA MVA MVA MVA MVA MVA MVA MVA  
 MVA MVA MVA MVA MVA MVA MVA MVA MVA MVA  
 MVA MVA MVA MVA MVA MVA MVA MVA MVA MVA  
 MVA MVA MVA MVA MVA MVA MVA MVA MVA MVA  
 MVA MVA MVA MVA MVA MVA MVA MVA MVA MVA  
            
      
            
      serum      
 serum     serum      
 serum     serum      
 serum     serum      
 serum     serum      
 serum     serum      
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 1 hour at 37°C 
6) Preparation & adding of the A3.01 cells: 
We need 0.5x106 cells in 50µl RPMI-10/well -> 50x106 cells in 5ml/plate 
1500 rpm, 5', 21°C, discard the SN 
Resuspend the pellet in 10ml RPMI-10 
Count the cells in a counting chamber (1/2 or 1/5 in Trypan Blue) 
1500 rpm, 5', 21°C, discard the SN 
Resuspend the pellet in 5ml RPMI-10 
Add 50µl cells/well to all wells (exept PBS-wells!) 
Mix well before and after adding! 
 2 hours at 37°C 
7) Over Night incubation: 
1500 rpm, 5', 21°C, discard the SN 
2x wash with 200µl RPMI-10, 1500 rpm, 5', 21°C, discard the SN 
Resuspend the cells in 110µl RPMI-10 and transfer to a in a 96well plate flat-bottomed, fill 
the wells around with 100µl PBS 
 over night at 37°C (approx. 16 hours) 
8) Fixation: 
Resuspend the cells and transfer to a 96well plate U-bottomed 
1500 rpm, 5', 21°C, discard the SN and resuspend the cells in 300µl of fixation solution 
Detection of vaccinia specific antibodies in ELISA 
Maxisorp plates (Nunc, Wiesbaden, Germany) were coated with sucrose-gradient purified 
MVA (at a protein concentration of 1µg/ml) for 3 h at 37 °C and overnight at 4 °C. The plates 
were blocked with PBS containing 0.05% Tween 20 and 10% FCS for 60 min at 37 °C. After 
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incubation of sera for 60 min at 37 °C, plates were washed five times with PBS. Then, a 
secondary anti-human immunoglobulin alkaline phosphatase conjugate was added for 30 min. 
According to the assay, affinity purified anti human IgG, IgM or IgG/IgM (Jackson 
ImmunoResearch, West Baltimore Pike, PA) were used. Following five washes, the plates 
were incubated with pNPP substrate (Sigma, Taufkirchen, Germany) at 37 °C, and the optical 
density was measured after 20 min at a wavelength of 405 nm. Eight dilutions (1:100 to 
1:12,800) were tested for each sample and the obtained ODs were used to calculate units of 
AUC. Alternatively, plates were coated with 0.25 μg/ml of recombinant A27R or A33R 
protein overnight at room temperature and  blocked with PBS containing 1% Tween (PBS-T) 
and 3% BSA for 2 hours at 37 °C. Sera were diluted in PBS-T and incubated for 60 min at 37 
°C. After six washes with PBS-T, anti-human IgG/IgM peroxidase (Jackson ImmunoResearch) 
was added to the plate and incubation carried out for 1 hour 37 °C. Following 5 washes, the 
plate was incubated for 30 min with ABTS substrate (Sigma) before the measurement of the 
optical density at 405 nm. For each sample three dilutions (1:50 to 1:200) were tested and the 
obtained ODs were used to calculate units of AUC. 
Results and Discussion 
Rationale for the use of the MVA-HIV-1nef vector 
Vaccinia viruses engineered to produce recombinant proteins are promising vaccine 
candidates. However, in HIV infected individuals due to concerns about the side effects of the 
classical replication competent vaccinia virus, the delivery of HIV genes require the use of 
highly attenuated replication defective vaccinia virus strains. One such virus strain, MVA was 
chosen for our study. From a safety perspective, MVA was used as a smallpox vaccine in over 
120,000 recipients without significant adverse reaction (Mayr et al., 1975). Moreover, in non-
human primate models of AIDS, MVA vectors engineered with HIV derived genes resulted to 
be capable to confer protection against disease progression after viral challenge (Amara et al., 
2002a; Amara et al., 2001; Amara et al., 2002b). 
HIV-1 Nef is an early expressed regulatory protein, which plays an important immune-
modulatory role. In fact, Nef is responsible for the downregulation of CD4, HLA class I and 
CCR5 on the surface of HIV infected cells. Moreover, Nef changes the activation state of the 
cells (Simmons et al., 2001). In vivo, Nef is essential for the maintenance of high levels of 
viral replication and progression to AIDS in SIV-infected monkeys. In humans, functional 
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deletions in the Nef gene have been shown to influence progression to AIDS (Learmont et al., 
1999). 
All these observations indicate that Nef is an essential protein for the pathogenesis of HIV. 
Thus, Nef represent an attractive component of HIV to be targeted in order to face the virus. 
One important issue to be addressed is which HIV genes have to be included in a candidate 
vaccine against AIDS. The multi-protein approach, while partially eliminating the problem of 
the choice of the genes, does not give information on the immunogenicity at the single gene 
level. Thus, the information provided by the multi-protein approach does not permit to 
improve the vaccine in term of composition. 
Our approach has as final target to evaluate the ability of the MVA-Nef vaccine to elicit an 
immune response and to improve the immune control of HIV in chronically HIV-1 infected 
individuals. We want also to collect information about the immunogenicity of Nef alone in 
order to build a collection of data to be used for the development of new vaccines against HIV. 
Characterization of the MVA-nef vector 
Expression in chicken embryo fibroblast 
The MVA vector expressing the HIV-1LAI Nef gene was first characterized on chicken 
embryo fibroblast (CEF). CEF are usually used to amplify preparations of recombinant MVA 
(Sutter and Staib, 2003). The use of CEF monolayer and serial dilutions of the MVA vector 
ensure the visualization of single plaques generated by single infectious units. Nef expression 
was detected in all the plaques (Figure IX), demonstrating the purity and stability of the 
MVA-nef vector. 
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Figure IX: Immunostaining of a typical MVA plaque on CEF. CEF monolayer infected with different 
dilutions of MVA-nef were fixed and stained with a polyclonal rabbit serum specific to Nef. Anti-rabbit 
HRP conjugated secondary antibody and dianisidine substrate were used to develop the assay. A 
representative plaque generated by infection with MVA-nef is shown. The darker cells express the Nef 
protein. 
This staining confirmed the stability of the MVA-nef vector. However, further experiments in 
human cells are required to asses the expression of Nef in a system relevant for the successive 
use of the vector as a vaccine in humans beings. 
Expression in human B-LCL 
Expression of the Nef protein in MVA-nef infected human B-LCL was measured by 
intracellular staining and Western blot. Intracellular staining showed that in more than 50% of 
the cells the Nef protein was detectable at 16 hours post-infection. A representative histogram 
plot obtained with MVA-nef infected B-LCL from individual 3975 is shown in Figure X. 
Similar results were obtained with individuals 4097 and 063 B-LCL (data not shown). The 
same samples were analyzed for the expression of Nef in Western blot. A band with a 
molecular weight of 27 kDa corresponding to Nef was detected in all three samples (Figure 
X). 
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Figure X: Nef protein expression in MVA-nef infected B-LCL analyzed by intracellular staining and 
Western blot. B-LCL were infected with 8 pfu/cell of MVA-nef or MVA-wt and incubated overnight at 
37°C in 5% CO2. As additional control, B-LCLs were mock infected. The Nef-specific mAb 3E6 followed 
by a FITC-conjugated goat anti mouse antibody was used for the intracellular staining. The same cells 
were analyzed in Western blot using the Nef-specific mAb 3D6. 
Functional characterization 
The capacity of Nef to downregulate the surface expression of HLA class I molecules was 
measured in the three B-cell lines used in Figure X. B-LCL were infected as described above 
with MVA-nef or MVA-wt and surface expression of HLA-A,-B,-C, HLA-C  and HLA class 
II molecules was measured in flow cytometry (Figure XI). The mAb W6/32 (Serotec) was 
used to measure the expression of HLA-A,-B and –C molecules while the mAb L31 (Setini et 
al., 1996) was used to specifically measure the expression of HLA-C molecules. The mAb 
WR18 (Serotec) was used to detect HLA-class II molecules. The total surface expression of 
HLA class I decreased upon infection with MVA-nef in all the B-LCL tested while no 
differences were observed in the expression of HLA-C between MVA-nef and MVA-wt 
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infected B-LCL. The surface expression of HLA class II was only slightly affected by the 
expression of the Nef protein. 
 
Figure XI: Functional characterization of the Nef protein expressed by the MVA-nef vector in different B-
cell lines. B-LCL were infected with 8 pfu/cell of MVA-nef or MVA-wt and incubated overnight at 37°C in 
5% CO2.  Each panel represents a B-LCL derived from a different individual. 
To characterize further the functionality of the Nef protein encoded by MVA-nef, a human 
CD4+ T-cell line (A3.01) was used. The intracellular expression of the Nef protein together 
with the surface expression of CD4 and HLA class I were evaluated after infection with 
MVA-HIV-nef, MVA-SIVmacJ5-nef or wtMVA. The Nef protein was expressed in 80% of 
the cells with mean fluorescence intensity (MFI) of 109 (data not shown). As shown in Figure 
XII, the CD4 expression was downregulated from an MFI of 265 to 54 in more than 90% of 
the cells. As expected we observed a selective downregulation of HLA-A and –B (from an 
MFI of 83 to 48) but not HLA-C molecules (Figure XII). 
 
Figure XII: Functional characterization of the Nef protein expressed by the MVA-nef vector in the A3.01 
T-cell line. Cells were infected with 8 pfu/cell of MVA-HIV-nef, MVA-SIVmacJ5-nef or wtMVA for 3 
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hours and after 16 hour at 37°C in 5% CO2 the expression of HLA class I, HLA-C and CD4 molecules was 
evaluated in flow cytometry. 
These results showed that the MVA-nef vector can be used to express the Nef protein in 
human cells and that this protein was functional concerning its capacity to downregulate CD4 
and HLA class I molecules. 
Characterization of the ability of the MVA-nef vector to present Nef derived 
epitopes 
Viral interference with MHC-class I molecules is considered an important mechanism of 
immune escape adopted by several viruses that infect humans (Alcami and Koszinowski, 
2000). HIV Nef protein downregulates HLA-A and B but not HLA-C and -E alleles (Le Gall 
et al., 1998; Schwartz et al., 1996). This selective Nef-mediated downregulation of HLA class 
I molecules was shown to correlate with protection of infected primary T lymphocytes from 
killing by CTL (Cohen et al., 1999) and from lysis by NK cell (Collins et al., 1998). The 
downregulation of HLA-A and –B molecules in MVA-nef infected T and B-cells might 
impede the correct presentation of Nef epitopes to specific CD8 T-cells, thus decreasing the 
capacity of the vaccine in inducing Nef-specific CD8 responses.  
To address the effect of the MVA-nef induced HLA class I downregulation on antigen 
presentation, we used B-LCL infected with MVA-nef and T-cell lines specific for defined Nef 
epitopes. Nef specific T-cell lines derived from HIV-1 infected patients were mixed with 
different amounts of autologous B-LCLs infected with MVA-nef or MVA-wt. As an 
additional control mock-infected B-LCL were used. After five hours of co-incubation, IFN-γ 
and IL2 production in CD3+ CD8+ cells were determined using intracellular cytokine staining. 
MVA-nef infected B-LCLs were able to stimulate the production of IFN-γ in all the four T-
cell line tested (Figure XIII). The percentage of IFN-γ producing cells at the maximal T/E 
ratio varied from 3.5% to 35% of the total CD3+ CD8+ cells. Only the T-cell line restricted to 
B35 and B7 were able to respond to the antigenic stimulation producing IL2 (Figure XIV). Of 
note, an MVA-wt specific response with production of IFN-γ and IL2 was observed with the 
B35 restricted T-cell line. Since this T-cell line was derived from an MVA-nef vaccinated 
subject, we cannot exclude a contamination by MVA-specific CD8 T-cells during the 
expansion of the Nef specific T-cells. 
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Figure XIII: Expression of IFN-γ in T-cell lines stimulated with MVA-nef infected B-LCL. Nef specific 
CD8 T-cell lines were stimulated with B-LCL infected with MVA-nef (red), MVA-wt (green) or mock 
infected (black) and stained for the expression of intracellular cytokines. Each graph represents a 
different CD8 T-cell line stimulated with autologous B-LCL. Different amounts of B-LCL were used and 
the Target / Effector ration is shown on the x axis. Epitope specificity and HLA restriction are indicated in 
each graph. 
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Figure XIV: Expression of IL2 in T-cell lines stimulated with MVA-nef infected B-LCL. Nef specific CD8 
T-cell lines were stimulated with B-LCL infected with MVA-nef (red), MVA-wt (green) or mock infected 
(black) and stained for the expression of intracellular cytokines. Each graph represents a different CD8 T-
cell line stimulated with autologous B-LCL. Different amounts of B-LCL were used and the Target / 
Effector ration is shown on the x axis. Epitope specificity and HLA restriction are indicated in each graph. 
As positive control, B-LCLs were loaded with the peptides recognized by the respective T-
cell line. As expected, peptide loaded B-LCLs were able to stimulate strongly the specific T-
cells (Figure XV). IFN-γ production varied between 43% and 72% of the total CD3+ CD8+ 
cells. Of note, the B8 and Cw7 restricted T-cell lines that did not produced IL2 after 
stimulation with MVA-nef infected B-LCL, produced low amount of IL2 after the strong 
stimulation provided by the peptide loaded B-LCL. Thus, the absence of IL2 production in 
these T-cell lines was not a consequence of the Nef expression in the antigen presenting cells 
but it is an intrinsic characteristic of the specific T-cell lines. 
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Figure XV: Expression of IFN-γ and IL2 in T-cell lines stimulated with MVA-nef infected B-LCL. Nef 
specific CD8 T-cell lines were stimulated with B-LCL loaded with peptides corresponding to the epitopes 
recognized by the autologous B-LCL or they were infected with MVA-nef (red), MVA-wt (green) or mock 
infected (black). After 5 hours of stimulation, cells were stained for the expression of IFN-γ and IL2. The 
quadrant gate in the pseudo color dot plots define the percentages of CD8+ T-cell that produce only IFN-γ, 
only IL2 or both. The HLA restriction of the different T-cell lines is indicated on the right of the panel. 
Stimulation is indicated on the top of the panel. Only the graphs representing a Target / Effector ratio of 5 
/ 1 are shown. 
Similar results were obtained using a classical chromium release assay. The four epitopes 
specific T-cell lines were able to lyse efficiently B-LCL infected with the MVA-nef vector 
(data not shown). Altogether, these results indicate that Nef epitopes are generally presented 
by antigen presenting cells as B-LCL after infection with MVA-nef. 
 
In summary, we demonstrated that the MVA vector expressing the HIV-1LAI Nef gene is able 
to express Nef in chicken embryo fibroblast, immortalized human B-cells (B-LCL) and 
human CD4 T-cell lines. The expressed Nef protein is functional in regard to its capacity to 
selectively downregulate HLA-A and –B molecules and CD4. Finally, Nef epitopes are 
correctly presented to the immune system by professional APC infected with MVA-nef. 
Therapeutic vaccination with MVA-HIV-1 nef in chronically HIV-1 
infected individuals. 
Description of the phase I vaccination trial 
Ten chronically HIV-1 infected patients were included in the study according to the following 
inclusion criteria: 
• Male or female subjects, aged >18 years 
• Asymptomatic HIV-infection with two documented positive HIV-1 antibody tests 
• Stable on anti-retroviral therapy for at least 6 months 
• Karnofsky performance status >80% 
• CD4 cell counts above 400/microliter (mean of two determination) 
• Written informed consent signed prior to study entry 
• Negative pregnancy test 
Exclusion criteria were the following: 
• Uncontrolled infection i.e. not responding to antimicrobial therapy 
• Recent (less than 6 months) myocardial infarction 
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• Creatine > 2mg/dl 
• Hemoglobin (Hb) <9g/dl 
• Leukocytes <3000/microliter 
• Platelets<50000/microliter 
• Liver function Tests (LFT) > 5x upper limit of normal 
• Any continuoos therapy that may influence CD4 counts other than anti-retroviral 
therapy 
• Any immune modifying therapy within 4 weeks prior to entry 
• Participation in any other investigational drug trial 
 
Ten subjects matching the entry criteria received three immunizations given by subcutaneous 
route at week 0, 2 and 16. Each vaccine dose consisted of 5 x 108 infectious units of MVA-
HIV-1LAI-nef in 1ml of phosphate buffer. Blood was collected for three times before vaccine 
administration, after each vaccine administration and one year after the third vaccination as 
shown in Figure XVI.  
 
 
Figure XVI: Timing of vaccination and blood cells collection 
Safety of the MVA-nef vaccination 
The vaccine was safe and we did not observed any adverse reaction for the entire follow up. 
In particular, total CD4 counts and viral load were maintained for all the study period and no 
changes associated with the vaccine administration were observed. For a detailed description, 
see Cosma et al. (Cosma et al., 2003). 
Characterization of the Nef-specific cellular immune response 
CD8 and CD4 T-cell immune responses were assessed using an IFN-γ based intracellular 
cytokine staining (ICS). Pools of overlapping peptides were used to stimulate freshly isolated 
PBMC before staining for extracellular markers (CD3, CD8 and CD4) and intracellular IFN-γ. 
The pools used to stimulate the PBMC are shown in Table III. The immune response to Nef 
Timeline (week) 
Vaccination: 
PBMC collection: 
-6  -4    0  2  4    8        16  18  20            32                      1 year 
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was characterized using both 20mer overlapping by 10 and a selection of optimal CD8 
epitopes (Nef Opt). As controls, we used pools of overlapping peptides derived from the HIV 
regulatory proteins Tat and Rev, and from the HIV structural proteins p17 and p24. 
Table III 
Protein Peptide length Overlap HIV-1 strain 
Nef 20mer 10 LAI 
Nef (Nef Opt) 8 to 11 Not overlapping LAI and SF2 
Tat 20mer 10 LAI 
Rev 20mer 10 LAI 
p17 15mer 5 SF2 
p24 20mer 10 SF2 
 
Before the administration of the MVA-nef vaccine, all the 10 subjects showed a CD8 Nef-
specific immune response at least against one of the two Nef pools tested (Figure XVII A and 
C, and Figure XVIII). During the longitudinal follow up of the CD8 T-cell response, we 
observed a clear increase of the Nef-specific immune response temporally associated with the 
vaccine administration in subject 8 and 10. While in the other eight subjects an association 
between vaccination and increase of the Nef-specific CD8 immune response was not evident 
(Figure XVIII). CD4 immune response to Nef was present only in two subjects before the 
administration of the vaccine (subject 3 and 10). Interestingly, after the first vaccine 
administration at week 2, eight out of ten subjects showed an increased CD4 immune 
response to Nef (Figure XVII C and Figure XIX) and this response was boosted after the 
second and third vaccination in subject 4 and 10. Of note in subject 10, we were able to detect 
1% of CD4 T-cells specific to Nef after the third vaccination at week 18. For a detailed 
description see also Cosma et al. (Cosma et al., 2003). The follow up of the CD8 and CD4 
immune response to Tat, Rev, p17 and p24 was carried out in parallel to the characterization 
of the Nef-specific immune response to monitor changes in the anti-HIV immune response 
and verify the specificity of the Nef-specific responses elicited by the vaccine. CD8 immune 
responses to Tat, Rev, p17 and p24 remained mostly unchanged during the follow up (Figure 
XX). Five out of ten subjects showed already a p24-specific immune response to Nef before 
the vaccine administration and in two of them (subject 3 and 8) an increase of the p24-specific 
CD8 immune response was detected after the first and the second vaccination, respectively. 
Subject number 1 had a strong and variable immune response to Tat for all the follow up 
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period. Similarly, CD4 immune responses remain unchanged and almost undetectable for all 
the time of the study (Figure XXI). However, in subjects 1, 3 and 8, we observed an increase 
of the p24-specific CD4 immune response temporally associated with the vaccine 
administration. In summary, except for the p24-specific immune response, temporally 
associated variations of the immune response directed to the other HIV-1 proteins tested were 
not detected. 
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Figure XVII: CD8 and CD4 T-cell responses to Nef.  Tukey Whiskers plots of the CD8 (A, B) and CD4 (C) 
responses to Nef measured using overlapping peptide (A, C) or a pool of optimal CD8 epitopes (B) are 
shown for each time point. The red arrows indicate the time of vaccination. The asterix indicates a p value 
< 0.05 using a Wicoxon matched pair test. 
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Figure XVIII: Follow up of the CD8 T-cell responses to Nef. PBMC were stimulated with 20mer peptide 
overlapping by 10 (closed square) or a pool of optinal CD8 epitopes (open circles). Each graph depicts the 
immune response observed in one individual. The arrows indicate the time of vaccination. 
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Figure XIX: Follow up of the CD4 T-cell responses to Nef. PBMC were stimulated with 20mer peptide 
overlapping by 10 (closed square) or a pool of optimal CD8 epitopes (open circles). In this case, the pool of 
optimal CD8 epitopes serve as negative control. Each graph depicts the immune response observed in one 
individual. The arrows indicate the time of vaccination 
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Figure XX: Follow up of the CD8 T-cell responses to Tat (open circle), Rev (asterix), p17 (closed circle) 
and p24 (open triangle). Each graph depict the immune response observed in one individual. The arrows 
indicate the time of vaccination. 
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Figure XXI: Follow up of the CD4 T-cell responses to Tat (open circle), Rev (asterix), p17 (closed circle) 
and p24 (open triangle). Each graph depict the immune response observed in one individual. The arrows 
indicate the time of vaccine administration. 
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Characterization of the long-lasting memory immune response 
One year after the last vaccine administration, we assessed if the CD4 immune response 
elicited by the vaccination was still detectable in the eight responder individuals. It was not 
possible to include subject 3 in our study, since he interrupted the antiretroviral therapy 
immediately after the end of our study without the advice of the physicians. All the other 7 
patients continued to assume regularly the antiretroviral therapy and blood samples were 
collected to measure the residual CD4 response specific to Nef. Results are shown in Figure 
XXII. 
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Figure XXII: Characterization of the Nef-specific CD4 immune response one year after the last vaccine 
administration.  The following subjects are shown: 1, 4, 6, 7, 8, 10 and 11. 
CD4 T-cells producing IFN-γ after stimulation with the pool of Nef derived peptides were 
detected in all the seven subjects and frequencies were significantly higher than frequencies 
detected before the administration of the vaccine in the same subjects (p=0,0156, Wilcoxon 
signed rank test). Thus, the MVA-nef vaccine was able to elicit a long lasting CD4 immune 
response specific to Nef. 
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Comparison between the immune response elicited by MVA-nef and 
the immune response observed in LTNP 
To understand better the quality of the immune response elicited by the MVA-nef vaccine, we 
analyzed the Nef-specific CD4 and CD8 immune response in a cohort of chronically HIV 
infected individual and in a cohort of long term non-progressor. As controls, CD4 and CD8 
immune responses specific to Tat, Rev, p17 and p24 were also screened. Specific immune 
responses were defined by IFN-γ production in CD8 and CD4 T-cells after stimulation with 
pools of overlapping peptides (see Table III). 
The cohort of chronically HIV infected individuals was composed of 18 individuals 
diagnosed as HIV-1 infected for a median of 71 months (range 26 to 183 months) and treated 
for a median of 62 months (range 23 to 171 months). The median CD4 count was 513 
cells/mm3, with a range between 285 and 1110 cells/mm3. Seven individuals had detectable 
but low viral loads ranging from 105 to 20417 copies RNA/ml. In all the other individuals, the 
viral load was less than 50 copies RNA/ml. The clinical characteristic of the single patients at 
the time of sample evaluation are shown in Table IV. 
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Table IV Clinical characteristic of the 18 chronically HIV infected subjects 
Patient ID Date of birth 
HIV+ 
diagnosis 
(months) 
Antiretroviral 
treatment 
(months) 
Plasma viral 
load (RNA 
copies/ml) 
CD4 cells 
counts 
(cells/mm3) 
01-0910 25/4/1957 99 96 15849 334 
01-1610 6/1/1942 70 56 1122 285 
01-2310 27/3/1956 109 57 50 737 
02-0910 5/8/1977 26 23 1047 502 
03-0910 30/5/1948 116 110 2455 444 
03-1610 17/9/1940 183 171 118 780 
04-2310 3/8/1960 62 58 50 524 
04-1610 25/1/1965 60 59 50 588 
05-2310 10/1/1959 63 61 50 317 
05-1610 24/1/1948 72 70 105 459 
06-1610 8/5/1945 65 63 20417 634 
09-2210 29/3/1954 115 59 50 1110 
01-1003 1/2/1962 76 75 50 969 
02-1003 20/6/1970 116 74 50 609 
03-1003 30/5/1966 72 69 50 347 
04-0604 9/11/1969 45 44 50 334 
05-1904 22/9/1943 55 53 50 688 
06-1904 2/8/1967 66 64 50 455 
 
The characteristics of the ten chronically HIV infected individuals enrolled in the MVA-nef 
vaccination trial, sampled six weeks before the administration of the vaccine, are shown in 
Table V. They were diagnosed as HIV-1 infected for a median of 124 months (range 25 to 
209 months) and treated for a median of 61.5 months (range 24 to 146 months). The median 
CD4 count was 565.5 cells/mm3 (range 407 to 1421 cells/mm3). Eight individuals had 
undetectable viral load while in two had detectable but stable viral load. 
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Table V Clinical characteristic of the 10 chronically HIV infected subjects enrolled in the MVA-nef 
vaccination trial 
Patients Date of birth 
HIV+ 
diagnosis 
(months) 
Antiretroviral 
treatment 
(months) 
Plasma viral 
load (RNA 
copies/ml) 
CD4 cells 
counts 
(cells/mm3) 
1 6/10/1959 185 54 50 407 
2 13/8/1944 149 64 6077 803 
3 3/7/1955 209 66 8710 1116 
4 23/6/1955 48 34 50 1421 
5 11/3/1962 187 66 50 584 
6 22/5/1937 99 41 50 782 
7 1/7/1949 66 60 50 473 
8 6/7/1960 83 63 50 549 
10 16/7/1963 197 146 50 488 
11 6/1/1962 25 24 50 488 
 
Statistical analysis did not reveal any significant difference between the ten chronically HIV 
infected individuals enrolled in the MVA-nef vaccination trial and the group of 18 chronically 
HIV-1 infected subjects (Figure XXIII). Therefore, the 18 chronically HIV-1 infected 
individuals were taken as reference group to study changes in the status of the immune 
response following MVA-nef vaccination. 
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Figure XXIII: Comparison between the clinical characteristics observed in 18 chronically HIV-1 infected 
individuals (CHI) and in the 10 chronically HIV-1 infected individuals enrolled in the MVA-nef study 
(MVA-nef study).  
The cohort of LTNP was composed of 12 individuals. All the subjects were antiretroviral 
naïve at the time of sample evaluation and were diagnosed as HIV-1 infected between 58 and 
228 months (median 200 months). The viral load ranged from 214 to 91201 copies RNA/ml 
(median 1600 copies RNA/ml) and total CD4 counts ranged from 134 to 626 cells/mm3 
(median 338 cells/mm3). The characteristic of the single patients at the time of sample 
evaluation are shown in Table VI. 
Table VI: Clinical characteristics of the 12 LTNP 
Patients Date of birth 
HIV+ 
diagnosis 
(months) 
Antiretroviral 
treatment 
(months) 
Plasma viral 
load (RNA 
copies/ml) 
CD4 cells 
counts 
(cells/mm3) 
L1 4/2/1948 210 - 3631 354 
L2 9/5/1965 217 - 31623 377 
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L3 25/4/1961 190 - 1023 276 
L4 15/10/1970 115 - 8511 322 
L5a 1/2/1962 213 - 91201 281 
L6 22/9/1953 225 - 214 626 
L7 24/5/1958 195 - 1300 134 
L8 19/1/1952 160 - 720 466 
L9 31/10/1961 205 - 1100 421 
L10 5/9/1964 58 - 1400 204 
L11 22/6/1961 228 - 1800 274 
L12 14/7/1953 101 - 2400 525 
 
To compare the immune response elicited by the MVA-nef vaccine with the immune 
responses usually observed in LTNP and chronically HIV infected subjects, we decided to 
consider the maximal immune response observed after vaccine administration during the 32 
weeks study period in the 10 vaccinated subjects. In keeping with the results shown 
previously, the median Nef-specific CD4 response after vaccine administration was 
significantly higher than the median observed before the administration of the vaccine (Figure 
XXIV). Interestingly, the median Nef-specific CD4 response was also significantly higher 
than the median observed in 18 chronically HIV-1 infected individuals, thus demonstrating a 
significant change not only in comparison to the previous responses but also in comparison to 
the general responses observed in chronically HIV-1 infected individuals. When we analyzed 
the Nef-specific CD4 T-cell responses in a cohort of LTNP (Table VI), we observed a 
heterogeneous response. Seven LTNP did not show Nef-specific CD4 responses, while five 
LTNP showed responses similar to the MVA-nef vaccinated subjects. These data suggest that 
the MVA-nef vaccine is able to stimulate Nef-specific CD4 responses with a magnitude 
similar to that observed in LTNP. The analysis of the Nef-specific CD8 responses did not 
reveal major differences between study subjects sampled before and after vaccination. 
However, CD8 Nef responses in the chronically HIV-1 infected individuals enrolled in the 
MVA-nef study were in general higher than CD8 Nef responses in the reference cohort of 
HIV-1 infected individuals (Figure XXIV). As control immune response to Tat, Rev, p17 and, 
p24 were analyzed in chronically HIV-1 infected subjects and LTNP (Figure XXV). CD4 
responses to p17 and p24 were detected more frequently in LTNP than in chronically HIV-1 
infected individuals. Eight out eleven (72%) LTNP showed a significant CD4 T-cell response 
to p24 while only six out of eighteen (33%) showed the same response in chronically HIV-1 
infected individuals. A similar pattern was observed for the p17 specific CD4 responses. CD8 
responses to p24 were equally found in LTNP and chronically HIV-1 infected individuals. 
However, the magnitudes of the responses were higher in LTNP. No differences between 
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LTNP and chronically HIV-1 infected individuals were observed for immune responses 
specific to Tat and Rev. 
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Figure XXIV: The Nef-specific CD4 responses elicited by MVA-nef are similar to CD4 responses observed 
in LTNP. Comparison of Nef-specific CD8 and CD4 responses measured in chronically HIV-1 infected 
subjects (C), LTNP (L), study subjects before (0) and after MVA-nef vaccination (m). Immune response 
were determined measuring the production of IFN-γ following stimulation with Nef derived peptides as 
described previously. The median is shown for each group. 
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Figure XXV: Analysis of the CD4 and CD8 immune responses in LTNP and chronically HIV-1 infected 
individuals. CD4 (A and B) and CD8 (C and D) responses were measured in LTNP (B and D) and 
chronically HIV-1 infected individuals (A and C). Each point represents one individuals. Median is shown 
for each cohort and antigen tested. Dotted lines represent the cut off for a positive CD8 and CD4 response. 
As previously discussed, a clear correlate of protection does not exist. However, we can 
deduce that our MVA-nef vaccine was able to change the immunological status of the 
vaccinated chronic HIV-1 infected individuals, rendering them more similar to LTNP. 
Obviously, this change is focused only on the Nef-specific immune response. 
Evaluation of MVA as alternative vaccine against smallpox 
Although increasing evidences in animal models suggest that MVA might be an alternative 
vaccine against smallpox for individuals at risk of the side effects induced by the classical 
smallpox vaccine (Belyakov et al., 2003; Earl et al., 2004; Wyatt et al., 2004), the immune 
responses elicited by MVA in these high risk individuals have not yet been characterized. In 
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addition, in our study we notice that the only subject not receiving smallpox vaccination in his 
childhood demonstrated the strongest immune response to Nef (Figure XXVI). Therefore, in 
our study to evaluate safety and immunogenicity of the MVA-nef vector, we included a 
complete characterization of the vaccinia specific immune response elicited by the vaccine. 
 
Figure XXVI: In subject 10, following the MVA-nef vaccination we observed the higher frequency of 
CD4+ lymphocytes producing IFN-γ, a boost of the immune response at each vaccine administration and 
an expansion of the targeted Nef epitopes. 
Vaccinia specific immune responses were readily detected after MVA-nef 
vaccination 
Humoral immune responses were measured using an innovative neutralization assay 
developed in our laboratory (Cosma et al., 2004), together with a classical ELISA that used 
highly purified viral particles or recombinant vaccinia virus proteins. Cellular immune 
responses were measured using the same intracellular cytokine staining used to measure the 
Nef-specific immune response. In this case, however, PBMC were stimulated with autologous 
PBMC previously infected with MVA. MVA was able to elicit vaccinia specific humoral and 
cellular immune in all the ten vaccinated subjects (Figure XXVII) (Cosma et al., 2007). These 
responses were maintained over one year demonstrating the capacity of MVA to elicit long 
lasting immune responses. 
To assess whether humoral immune responses and CD8 T-cell responses were equally 
regulated we performed a Spearman’s rank correlation between neutralizing titers and % of 
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IFN-γ producing CD8 T-cells for all the time points tested. As shown in Figure XXVIII no 
correlations were found. For instance, subject number 2 who showed the lowest neutralizing 
activity demonstrated a strong CD8 T-cell response after the second MVA administration 
(0.37%) and maintained a strong response for one year (0.38%). Similarly, subject 10, the 
only one that was not vaccinated against smallpox as a child and in which we observed low 
titers of antibodies, demonstrated a strong CD8 T-cell response with 0.20% of IFN-γ 
producing cell after two MVA administrations, 0.46% after three MVA administrations and 
0.24% one year after the last immunization. 
Antibodies detected after vaccination with MVA were mainly of the IgG class 
A possible association between protection from monkeypox and presence of vaccinia specific 
IgG was recently described in SIV infected monkeys (Edghill-Smith et al., 2005a). SIV 
infected monkeys vaccinated with Dryvax or MVA followed by Dryvax were fully protected 
after a lethal monkeypox challenge only when their CD4 T-cell levels were above 300 
cells/mm3. Monkeys with CD4 T-cells levels above 300 cells/mm3 had high IgG titers and 
low IgM titers while highly immunocompromised monkeys with CD4 T-cells levels < 300 
cells/mm3 had low IgM and IgG titers. These data suggest that the presence of high titers of 
vaccinia specific IgG is a protection marker for monkeypox in monkeys and could be similar 
for smallpox in humans. 
Since CD4 T-cell counts in our cohort of chronically HIV-1 infected individuals were > 400 
cells/mm3 (Table VII), MVA should be able to induce high titers of vaccinia specific IgG. To 
verify this hypothesis, we performed an ELISA to measure vaccinia specific IgG and vaccinia 
specific IgM on the sera collected after the third MVA administration. 
As shown in Table VII, IgG titers ranged between > 25,600 and 1600 while IgM titers were 
significantly lower ranging between 200 and < 100 (Mann-Whitney U test, p < 0.0001). The 
observed IgG and IgM titers were consistent with titers observed in monkeypox protected 
monkeys (Edghill-Smith et al., 2005a).  
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Figure XXVII: MVA-specific humoral and cellular immune responses in MVA-nef vaccinated subjects. 
Samples were tested before MVA administration (0), after two immunizations (II), after three 
immunizations (III), and 1 year after the third immunization (1 Year). Humoral immune responses were 
measured using a neutralization assay and the neutralization capacity is expressed in terms of area under 
the curve (AUC). CD8 and CD4 T-cells specific to MVA were measured using an IFN-γ-based 
intracellular cytokine staining.  A cut off of 0.04% was applied to CD8 responses while a cut off of 0.03% 
was applied to CD4 responses. The cut off line is shown in each graph. 
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Figure XXVIII: Correlation analysis between humoral and cellular immune response to vaccinia virus. 
The correlation between neutralizing activity (MVA-gfp NT) and frequency of vaccinia specific CD8 T-
cells (% of IFN-γ+ CD8+ cells) was determined by Spearman’s rank correlation. R and P value are shown 
in each figure. The solid line represents a regression line. Data points relative to the individuals discussed 
in the text are indicated. Subject 10 was vaccinia naïve while subject 2 received smallpox vaccination as 
children. Since PBMC were not available, the cellular immune response for subject number 2 at (0) and 
subject number 4 at (III) were not assessed. 
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Table VII: ELISA titer and total CD4 counts. (0) before vaccination, (III) after the third vaccination 
CD4 counts  MVA ELISA 
 IgG/IgM  IgG  IgM Subject 
Baseline 
 0 III   III   III 
1 407  800 3,200  6,400  200 
2 803  400 1,600  1,600  100 
3 1116  800 3,200  12,800  100 
4 1421  400 3,200  12,800  100 
5 584  400 12,800  12,800  100 
6 782  800 12,800  12,800  <100 
7 473  400 3,200  6,400  <100 
8 549  1600 6,400  12,800  <100 
10 488  400 3,200  3,200  <100 
11 488  1600 >12,800   >25,600   100 
 
Eradication of smallpox demonstrated that the immune response elicited by the classical 
vaccination was remarkably effective. However, since variola virus is now eradicated, it is not 
possible to establish if the residual immunity still detectable in individuals vaccinated more 
than 30 years ago is protective. The same applies to immune responses elicited by alternative 
vaccines against smallpox such as MVA. Therefore, to determine the efficacy of the immune 
response elicited by MVA in chronically HIV infected subjects we characterized the vaccinia 
specific immune response in four healthy subjects that were recently vaccinated with the 
classical smallpox vaccine and/or MVA. Theoretically, these subjects should have a vaccinia 
specific immune response similar or higher to that that was present during the smallpox 
vaccination campaign. Vaccination status and results are summarized in Table VIII. Subject 
32 demonstrated the highest titer of neutralizing antibodies. The neutralizing titer was similar 
to the mean observed in chronically HIV-1 infected individuals one year after the last 
vaccination with MVA (Figure XXVII). In the same subject, cellular immune responses were 
under the limit of detection. The opposite pattern was observed in subject 33, 0.15% of CD8 
T cells specific to vaccinia virus were detected while the neutralization titer was low. Subject 
31 and 34 had a weak but detectable CD8 T cell response and intermediate neutralizing titers. 
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Overall, the immune responses detected were similar or lower than the average responses 
detected in chronically HIV-1 infected individuals vaccinated with MVA. 
Table VIII: Vaccinia specific immune response in subjects repeatedly vaccinated with the classical 
smallpox vaccination and MVA. Blood samples were collected in 2004. Cellular immune responses are 
expressed in terms of % of CD4 or CD8 T-cells expressing IFN-γ after stimulation with autologous MVA 
infected PBMC. 
   
Year of vaccination 
Humoral 
response 
(MVA-gfp 
NT) 
 
Cellular response Subject 
Vaccinia MVA  AUC   CD8 CD4 
31 1954, 1965, 1975 2001 46.2  0.06 0.02 
32 1970 2000, 2001 88.8  0.04 0.01 
33 childhood 2001 23.7  0.15 0.00 
34 1958, 1969, 1995, 2000 1990, 2000, 2001 57.7   0.05 0.03 
 
Analysis of the relationship between MVA-specific and Nef-specific immune 
responses. 
Following MVA-nef vaccination, we observed new immune responses directed to the 
encoded protein (Cosma et al., 2003) and the viral vector. The relationship between immune 
responses directed to the encoded Nef protein and to the MVA vector was assessed by means 
of correlation analysis. CD4 and CD8 T-cell responses to Nef were compared to CD4 and 
CD8 T-cell responses to MVA as well as to humoral immune responses to MVA measured by 
mean of ELISA and neutralization assay. Correlation coefficients and P values were 
calculated after two and three administrations of the vaccine, as well as for immune responses 
measured 1 year after the vaccination. Interestingly, we observed a significant inverse 
correlation between MVA-specific and Nef-specific CD4 T-cell responses after the third 
vaccination (Figure XXIX). Subjects with the lowest Nef-specific CD4 T-cell responses had 
the highest CD4 T-cell responses to MVA and vice versa. The correlation coefficient and the 
P values indicated a significant inverse correlation also when the subject with the highest CD4 
T-cell response to Nef (subject 10; r=-0.9507, p=0.0011) or the subject with the highest 
response to MVA (subject 2; r=-0.7454, p=0.0368) were excluded from the analysis. This 
correlation was not evident after two MVA-nef immunizations or one year after the last 
immunization, but only after the third immunization when we observed the peak of the MVA-
specific cellular response. This relationship highlights interference between MVA-specific 
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and Nef specific CD4 responses. CD8 T-cell responses to Nef correlated neither with cellular 
nor humoral MVA-specific immune responses at all the time points tested (data not shown). 
Nevertheless, the presence of a strong Nef-specific CD8 response before the administration of 
the MVA-nef vaccine might have masked a possible relationship.  
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Figure XXIX: Relationship between MVA-specific and Nef-specific CD4 responses after three 
administrations of the MVA-nef vaccine. The correlation between MVA-specific and Nef-specific CD4 
responses determined by IFN- based intracellular cytokine staining was determined by Spearman’s 
rank correlation analysis. R and P values are shown. Data points relative to the subjects discussed in the 
text are shown. The analysis was carried out on nine subjects since PBMCs from subject number 4 after 
the third vaccination were not available. 
In summary, MVA was able to elicit humoral and cellular immune responses to vaccinia virus 
in a cohort of chronically HIV-1 infected individuals undergoing HAART. Of note, the 
elicited immune responses were similar to responses that are considered protective in healthy 
subjects recently vaccinated with vaccinia and/or MVA. Unfortunately, immune interference 
was detected between Nef-specific CD4 responses and MVA-specific CD4 responses. 
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Discussion 
CD8 T-cell response is crucial in controlling the acute phase of HIV infection (Borrow et al., 
1994; Koup et al., 1994). However, in the chronic phase of the disease CD4 T-cell response 
seems to be important in controlling viral load as seen in LTNP (Pitcher et al., 1999; 
Rosenberg et al., 1997) and patients treated with HAART early during primary infection 
(Rosenberg et al., 2000). The MVA-nef vector is able to elicit and expand Nef-specific CD4 
immune responses in the majority of the vaccinated subjects, increasing both the magnitude 
and breadth of the immune response. These results suggest that CD4 T-cell responses could 
be stimulated in chronically HIV infected individuals by means of therapeutic vaccination. 
Moreover, MVA-nef vaccination is able to amplify the frequencies of CD4 lymphocytes 
specific to Nef to reach levels comparable or even higher to the ones observed in LTNP, 
indicating a modulation of the virus-specific immune status in these chronically HIV-1 
infected individuals.  
Whereas a CD4 T-cell response was clearly observed, the CD8 immune response specific to 
Nef elicited by MVA-nef was faint or absent. There are several potential explanations for the 
lack of a strong Nef specific CD8 immune response after MVA-nef vaccination: 1) the 
expression of the functional product of the nef gene might induce HLA class I downregulation 
in MVA-nef-infected antigen-presenting cells inhibiting the antigen presentation to CTL 
(Collins et al., 1998); 2) since all the subjects enrolled in the study showed a Nef specific 
CD8 immune response before vaccination (Nef pool: median 0,24%, min 0,01%; max 0,42%; 
Nef Opt pool: median 0,23%, min 0,08%, max 1,33%) the T-cell precursors specific to Nef 
might be exhausted; 3) because of the strong pre-existing Nef-specific CD8 response, weak 
responses elicited by the vaccine might be masked by high variability in the determination of 
the responses 4) the MVA vector might be more effective in inducing a CD4 T-cell response 
in this clinical setting. Nevertheless, the increase observed in subjects 8 and 10 together with 
the expansion of the breadth of the CD8 T-cell response in subject 1, indicates that the MVA-
nef vector is able to stimulate also CD8 T-cell responses. 
Of note, an increase of the CD8 and CD4 T-cell responses to p24 has been observed in some 
subjects immediately after vaccination (Figure XX and Figure XXI; subjects 3 and 8). 
Cytokine-driven bystander activation or stimulation of HIV-infected antigen-presenting cells 
by vaccine-elicited T-cells might explain the clonal expansion of T-cells specific for the p24 
antigen; indicating that undetectable precursors specific to p24 might be present in chronically 
HIV infected individuals. Moreover, these increases in the p24 specific immune response 
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suggest that the MVA-nef vaccine could promote epitope spreading towards other HIV 
proteins. 
Whether a clinical benefit can be achieved by MVA-nef vaccination, is an important issue that 
has yet to be addressed. However, several lines of evidence highlight the importance of virus-
specific T-helper cells in chronic viral infections. First, T-helper cells play a critical role in 
maintaining effective immunity in murine models of chronic viral infections (Battegay et al., 
1994; Matloubian et al., 1994). Second, successful treatment of acute HIV-1 infection in 
humans leads to augmentation of T-helper-cell immune responses and enhances the immune 
control of the HIV-1 infection (Rosenberg et al., 2000). Third, we found a relatively robust 
Nef-specific CD4 immune response in LTNP. Thus, the established importance of T-helper 
cells in controlling chronic viral infections together with the clear demonstration that a T-
helper immune response can be augmented in chronically HIV infected individuals using an 
MVA-nef vector provide a rationale to further explore immunotherapeutic intervention in 
chronic HIV-infection. More interestingly, the Nef-specific T-helper response detected after 
MVA-nef vaccination might suggest that the immunological status of these HIV chronic 
infected individuals was, at least for a limited period of time, similar to that described in 
LTNP. 
Finally, this clinical study shows for the first time that the highly attenuated vaccinia-virus 
vector MVA can be used as safe vector in a cohort of immuno-compromised individuals. We 
believe this pilot study establishes the scientific rationale for future use of the MVA vector in 
individuals for which the use of a not attenuated vaccinia vector is not advisable, such as 
patients who undergo cancer therapy, long-term corticosteroid therapy, organ transplant 
recipients and patients with congenital immunodeficiency disorders (Bartlett, 2003). We also 
demonstrate that recombinant MVA vaccines can elicit immune responses to a target antigen 
also in individuals that have been previously vaccinated against smallpox. Nevertheless, the 
most prominent Nef-specific immune response was found in subject 10, the one that was not 
previously immunised with vaccinia virus (Figure XXVI).  
In summary, the MVA-nef vector is able to safely elicit a CD4 T-cell immune response 
specific to Nef in a cohort of chronically HIV infected individuals, thus changing the chronic 
unbalanced immunological status of these subjects. These results suggest that a therapy 
interruption after MVA-nef vaccination might be valuable to further amplify HIV-specific 
immune responses. Of note, as shown in Figure XXII, Nef-specific CD4 T-cells elicited by 
the MVA-nef vaccine were still present one year after the third vaccine administration 
indicating that the MVA-nef vaccine is able to elicit long lasting T-helper memory cells. 
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Although increasing evidence from animal models suggests that MVA might be an alternative 
vaccine against smallpox for individuals at risk for the side effects induced by the classical 
smallpox vaccine (Belyakov et al., 2003; Earl et al., 2004; Slifka, 2005; Wyatt et al., 2004), 
the immune responses elicited by MVA in these high risk individuals have not yet been fully 
characterized. We characterized the vaccinia-specific immune responses elicited in ten 
chronically HIV-1 infected individuals undergoing HAART after three administrations of an 
MVA vaccine. Our results demonstrated that MVA was able to evoke strong and durable 
humoral and cellular immune responses. MVA was able to elicit vaccinia-specific immune 
responses in subjects that were vaccinated against smallpox as children and in one subject that 
was completely naïve to vaccinia. Thus, MVA was able to reestablish vaccinia-specific 
immune response in individuals vaccinated long ago and at the same time, it was able to elicit 
de novo vaccinia-specific immune responses. 
The analysis of the humoral immune response demonstrated that MVA was able to elicit both 
neutralizing and binding antibodies. Notably, the magnitude of the humoral immune response 
elicited by MVA was similar to that observed in healthy subjects repeatedly vaccinated with 
vaccinia and/or MVA. 
Of note, no correlation was found between humoral immune response and CD8 T-cell 
response. This observation is consistent with the analysis performed by Hammarlund et al. 
(Hammarlund et al., 2003) on a cohort of 306 individuals vaccinated against smallpox. 
Overall, the data demonstrated that specific antibodies and IFN-γ producing CD8 T-cells are 
two independent biomarkers. 
While neutralizing antibodies and CD8 T-cells were readily elicited in all subjects, vaccinia 
specific CD4 T-cells were observed in only 4 subjects. Several hypotheses may explain the 
lack of generalized CD4 T-cell responses to vaccinia. First, MVA may have a reduced 
capacity in inducing CD4 T-cell responses in this clinical setting. However, in the same 
subjects a strong CD4 immune response to the recombinant nef gene was observed (Cosma et 
al., 2003) confirming the capacity of MVA to elicit CD4 immune responses. Second, it may 
be possible that another cytokine is the basis for the vaccinia-specific CD4 immune response 
induced by MVA. Third, since this is a retrospective study, frozen PBMCs were used in all 
experiments and CD4 T-cells are more sensitive to freezing and thawing than CD8 T cells. 
Safety, capacity to accommodate different and not related genes and ability to stimulate the 
innate immune system make MVA an optimal vector to develop novel vaccines. However, the 
encoded protein has to compete against the numerous vector-derived antigens for T-cell 
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recognition. Therefore, antigen dominance and immune interference play an important role to 
determine the immunogenicity of the encoded product and the viral vector (Kedl et al., 2003). 
Our results demonstrated a significant inverse correlation between MVA-specific and Nef –
specific CD4 responses. A possible explanation for this relationship is the existence of a 
competition at the level of the CD4 responses. Our data indicate a general advantage for the 
CD4 T-cells specific to Nef and this advantage seems to be more pronounced in the vaccinia 
naïve subject number 10. If this is the case, the lack of a generalized CD4 T-cell response to 
vaccinia might be the consequence of antigen competition. 
The respective role of neutralizing antibodies, CD8 and CD4 T-cells in protection from 
smallpox is still poorly understood. Moreover, since eradication of smallpox preceded the 
advent of modern techniques to measure T-cell responses, such as intracellular cytokine 
staining, ELISPOT and tetramer staining, historical data on the protective vaccinia-specific 
immune response rely entirely on the analysis of the presence of vaccinia-specific antibodies 
and no comparisons with cellular immune responses exist. Recently, several studies have 
addressed this issue in animal models. Antibodies were found to be sufficient in protecting 
mice from a lethal challenge with vaccinia virus in the absence of specific CD8 immune 
response, while in the absence of antibodies, CD8 T-cells were able to prevent mortality and 
disease progression (Belyakov et al., 2003; Xu et al., 2004). In mice undergoing a secondary 
infection with ectromelia virus, antibodies were sufficient and necessary for protection while 
CD8 response failed in protecting mice from lethal ectromelia infection (Fang and Sigal, 2005; 
Panchanathan et al., 2006).  In immunocompromised monkeys, the presence of high titers of 
vaccinia specific IgGs have been shown to correlate with protection against a lethal 
monkeypox challenge (Edghill-Smith et al., 2005a). Finally, a recent report analyzing the 
immunological mechanism of protection in Rhesus macaques vaccinated with Dryvax and 
then challenged intravenously with monkeypox virus, demonstrated that specific antibodies 
are necessary and sufficient for protection (Edghill-Smith et al., 2005b). In the same report, 
depletion of CD8 and CD4 T-cells performed after vaccination did not affect the outcome of 
the subsequent challenge. Overall, studies performed in the Rhesus macaque model indicate a 
pivotal role of the humoral response, while some of the studies performed in the mouse model 
suggest an additional contribution of the cellular immune response. 
In our cohort of chronically HIV-1 infected individuals, the MVA vaccine fulfills the 
requirements of stimulating both neutralizing antibodies and specific CD8 T-cells. Moreover, 
we detected high titers of neutralizing IgGs. Thus, the data support our proposal to use MVA 
as an alternative smallpox vaccine in potentially immunocompromised individuals. 
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In a parallel study, a similar cohort of HIV-1 infected individuals was vaccinated with an 
MVA HIV-1 nef vector vaccine (Harrer et al., 2005). In this study, the characterization of the 
vaccinia specific immune response was limited to the measurement of specific IgG using an 
ELISA and specific CD8 T-cells using an ELISPOT assay. Consistent with our results, 
vaccinia specific IgGs were readily detected after the administration of the MVA vaccine. 
HIV-1 infected individuals are considered potentially immunocompromised and CD4 counts 
have been shown to predict the capacity of these individuals in mounting a correct immune 
response to a vaccine (Rodriguez-Barradas et al., 1992; Rousseau et al., 1999). Our data 
showed that in a cohort of chronically HIV infected subjects with CD4 T-cell counts between 
407 and 1421 cells/mm3, MVA was able to elicit a durable immune response.  
CD4 counts also predict the risk of adverse effects following classical vaccination against 
smallpox, likely because the immune system is better able to control the spreading of the 
replication-competent vaccinia virus classically used to vaccinate against smallpox. Some 
studies involving small numbers of patients indicated that the classical smallpox vaccination 
might be safe in subjects with CD4 counts >200 cells/mm3 (Tasker et al., 2004), while below 
this threshold adverse effects were observed. However, in the absence of large scale clinical 
trials the Centers for Disease Control and Prevention (Atlanta, GA) recommended against the 
use of the replication competent vaccinia virus to vaccinate individuals with HIV infection, 
regardless of their CD4 cell counts (Bartlett, 2003). Thus, replication-deficient MVA because 
of its immunogenicity and safety may represent a better alternative. Nevertheless, a series of 
limitations of the present study needs to be emphasized. The study was conducted on a cohort 
of chronically HIV-1 infected individuals undergoing HAART with CD4 count >400 
cells/mm3 and undetectable viral load. The ability of this specific cohort in mounting a MVA 
specific response is certainly better than what we can expect in a cohort of HIV-1 infected 
individuals with CD4 counts <400 cells/mm3 and detectable viral load. Therefore, further 
studies in cohorts of HIV infected individuals with CD4 counts <400 cells/mm3 and with 
higher viral loads are required. In addition, since 9 of the 10 HIV infected individuals 
received smallpox vaccination as children, the role of MVA in priming vaccinia specific 
immune responses rely only on the characterization of the immune responses observed in 
subject number 10 who was not immunized as a child. Further studies in cohorts of vaccinia 
naïve HIV infected individuals should corroborate whether the immune responses observed in 
this subject are characteristic of the priming capacity of MVA. Finally, the vaccine used in 
our study encoded the HIV-1 regulatory protein Nef. The Nef protein promotes HIV-1 
immune escape via the downregulation of CD28, CD4 and MHC class I and class II 
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molecules. Therefore, we cannot exclude such an effect in the context of the MVA vector. If 
this is the case, the wild type MVA might be more effective in eliciting vaccinia specific 
immune responses. 
This study provides a complete characterization of the vaccinia specific immune response  
following the administration of MVA to chronically HIV-1 infected individuals with a long 
history of antiretroviral treatment and with CD4 T-cells counts >400 cells/mm3. The observed 
immune response suggests that MVA can be used as alternative vaccine against smallpox in 
this specific cohort of individuals. 
Conclusions 
With this research, we demonstrate that the MVA HIV-1LAI nef vaccine is safe and 
immunogenic in chronically HIV-1 infected individuals under HAART. The observed Nef-
specific immune responses were similar in magnitude to responses usually detected in LTNP. 
In addition, the elicited responses were detectable one year after the administration of the 
third vaccination, thus demonstrating the capacity of the vaccine to elicit long lasting 
responses. 
The natural follow up of this study will be an efficacy trial in which therapy will be 
interrupted after the administration of the vaccine. 
In addition, since this study had a therapeutic setting, it will be useful to test the MVA HIV-
1LAI nef vaccine in a prophylactic study. 
Another important aspect of this study is the consideration that MVA can be used as 
alternative vaccine against smallpox in chronically HIV-1 infected individuals under HAART. 
This study highlighted also a potential problem of immune interference between Nef-specific 
immune responses and MVA-specific immune responses. Therefore, in the next trial we will 
also evaluate immune responses in vaccinia naïve individuals. 
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